19 October 2020  Confidential  Page 1 of 95 
 
  
 
Protocol ARQ -151-311 
 
A Phase 3, 4 -Week, Parallel Group, Double Blind, Vehicle -
Controlled Study of the Safety and Efficacy of ARQ -151 Cream 
0.15% Administered QD in Subjects with Atopic Dermatitis  
 
Sponsor:  Arcutis  Biotherapeutics , Inc.  
 [ADDRESS_140505] :  
 
 
  
 
Medical Monitor:     
  
  
 
 
 
IND Number:   
 
Protocol Version:  Original  
 
Protocol Date:  19 October 2020   
 
GCP Statement  
This study is to be performed in full compliance with the protocol,  International Conference on Harmonisation  
Good Clinical Practices ( ICH GCP), and applicable regulatory requirements. All required study documentation 
will be archived as required by [CONTACT_12721].  
 
Confidentiality Statement  
This document contains  confidential  information . It contains proprietary information of Arcutis  Biotherapeutics , 
Inc. Any viewing or disclosure of such information that is not authorized in writing by [CONTACT_125059] , 
Inc. is strictly prohibited. Such information may be  used solely for the purpose of reviewing or performing this 
study.  

Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 2 of 95 SITE  INVESTIGATOR SIGNATURE [CONTACT_1783]  
 
A Phase 3, 4 -Week, Parallel Group, Double Bli nd, Vehicle -Controlled Study of the Safety and 
Efficacy of ARQ -151 Cream 0.15% Administered QD in Subjects with Atopic Dermatitis  
 
ARQ -151-311 
 
SPONSOR:    Arcutis  Biotherapeutics , Inc.  
    [ADDRESS_140506]  
    Westlake Village, CA [ZIP_CODE]  
 
ISSUE DATE:   [ADDRESS_140507] this study as 
outlined herein, in accordance with the current International Conference on Harmonisation  Good 
Clinical Practices ( ICH GCPs)  and applicable local and regional regulations .  
 
I will provide all study personnel under my supervision copi[INVESTIGATOR_125026] , Inc. I will discuss the material with them to 
ensure that th ey are fully informed about ARQ -[ADDRESS_140508]’s consent form in the study file and providing each subject with a 
signed copy of the consent form.  
 
I agree to maintain the confidentiality of all information received or developed in connection 
with this protocol . 
 
Invest igational  Site Name:   
 
 
[CONTACT_125104]:    
 
 
Investigator Signature :   [CONTACT_1782]:   
 
  

Protocol ARQ -151-[ADDRESS_140509] Cream  ................................ ................................ ......................... 24 
2.3.2.  Psoriasis Phase 2a (ARQ -151-101) ................................ ................................ ............ 24 
2.3.3.  Psoriasis Phase 2b (ARQ -151-201) ................................ ................................ ............ 26 
2.3.4.  Atopic Dermatitis Phase 1 PK Study in Adults (ARQ -151-102) ............................... 28 
2.3.5.  Phase 1 Study in Adolescents and Pediatrics (ARQ -151-105) ................................ ...28 
2.3.6.  Atopic Dermatitis Phase 2 Dose Ranging Study (ARQ -151-212) ............................. [ADDRESS_140510] Tablet  ................................ ................................ .............................. 30 
2.4. Rationale for Development  ................................ ................................ ......................... 30 
2.4.1.  Dose Selection  ................................ ................................ ................................ ............ 31 
2.4.2  Risks and/or Benefits to Subjects  ................................ ................................ ............... [ADDRESS_140511] Participation  ................................ ................................ ................................ ...33 
4.4. Numbering of Subjects  ................................ ................................ ............................... 33 
Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 4 of 95 4.5. Selection of Study Population  ................................ ................................ .................... 34 
4.5.1.  Inclusion Criteria  ................................ ................................ ................................ ........ 34 
4.5.2.  Exclusion Criteria  ................................ ................................ ................................ .......35 
4.6. Randomization  ................................ ................................ ................................ ............ 37 
4.7. Study Restrictions  ................................ ................................ ................................ .......37 
4.7.1.  Prohibitions and Concomitant Therapy  ................................ ................................ ......37 
4.8. Treatment  ................................ ................................ ................................ .................... 39 
4.8.1.  Drug Suppli es, Packaging and Labeling  ................................ ................................ .....39 
4.8.2.  Blinding  ................................ ................................ ................................ ...................... 39 
4.8.3.  Breaking Treatment Codes  ................................ ................................ ......................... 39 
4.8.4.  Treatment Administration  ................................ ................................ ........................... 40 
4.8.5. Treatment Compliance  ................................ ................................ ................................ 41 
4.8.6.  Removal of Subjects from Study Treatment  ................................ .............................. 41 
4.8.7.  Removal of Subjects from the Study  ................................ ................................ .......... 42 
5. STUDY PROCEDURES  ................................ ................................ ............................ 42 
5.1. Safety Assessments  ................................ ................................ ................................ .....42 
5.1.1.  Screening  ................................ ................................ ................................ .................... 42 
5.1.2.  Contraception Requirements  ................................ ................................ ...................... 43 
5.1.3.  Baseline (Day 1)  ................................ ................................ ................................ ......... 44 
5.1.4.  Physical Examination  ................................ ................................ ................................ .44 
5.1.5.  Vital Signs, Height and Weight  ................................ ................................ .................. 44 
5.1.6.  Laboratory Tests  ................................ ................................ ................................ ......... 45 
5.1.7.  Patient Health Questionnaire depression scale (PHQ -8) ................................ ............ 46 
5.1.8.  Patient Health Questionnaire Depression Scale (Modified PHQ -A) .......................... 46 
5.1.9.  Children’s Depression Inventory 2  ................................ ................................ ............. 47 
5.1.10.  Columbia -Suicide Severity Rating Scale (C -SSRS) ................................ ................... 47 
5.1.11.  Local Tolerability Assessment  ................................ ................................ ................... 47 
5.1.12.  Adverse Events  ................................ ................................ ................................ ........... 49 
5.2. Effic acy Evaluations  ................................ ................................ ................................ ...49 
5.2.1.  Validated Investigator Global Assessment Scale for Atopic Dermatitis  .................... 49 
5.2.2.  Eczema Area and Severity Index (EASI)  ................................ ................................ ...[ADDRESS_140512]  Itch Numerical Rating Scale (WI -NRS)  ................................ .......................... 50 
Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 5 of 95 5.2.4.  Dermatology Life Quality Index (DLQI) and Children’s Dermatol ogy Life 
Quality Index (CDLQI)  ................................ ................................ .............................. [ADDRESS_140513] Questionnaire (DFI)  ................................ ......................... 51 
5.3. Other Evaluations  ................................ ................................ ................................ .......51 
5.3.1.  Body Surface Area (BSA)  ................................ ................................ .......................... 51 
5.3.2.  SCORAD  ("SCORing Atopic Dermatitis")  ................................ ................................ 51 
5.3.3.  Patient -Oriented Eczema Measure (POEM)  ................................ ............................... 51 
5.3.4.  Pharmacokinetics Assessment  ................................ ................................ .................... 52 
5.3.5.  Medical Photography  ................................ ................................ ................................ ..52 
5.4. Final Study Visit – End of Study  ................................ ................................ ................ 52 
5.5. Early Termination Visit  ................................ ................................ .............................. 52 
5.6. Unscheduled Visit  ................................ ................................ ................................ .......52 
5.7. Adverse Events  ................................ ................................ ................................ ........... 53 
5.7.1.  Adverse Event Definition  ................................ ................................ ........................... 53 
5.7.2. Serious Adverse Event Definition  ................................ ................................ .............. 53 
5.7.3.  Suspected  Unexpected  Serious Adverse Reaction (S[LOCATION_003]R)  ................................ .....[ADDRESS_140514] Reported Outcomes Analyses  ................................ ................................ ........ 62 
6.14.1.  Dermatology Life Quality Indexes,  Children’s Dermatology Life Quality 
Index , SCORAD and POEM  ................................ ................................ ...................... [ADDRESS_140515] Information and Consent/Assent  ................................ ................................ ...[ADDRESS_140516]  ................................ ................................ ................................ ......66 
7.9. Report Format  ................................ ................................ ................................ ............. 66 
7.10.  Publication Policy  ................................ ................................ ................................ .......66 
8. REFERENCES  ................................ ................................ ................................ ........... 66 
9. APPENDICES  ................................ ................................ ................................ ............ 68 
APPENDIX  1. BODY DIAGRAM  ................................ ................................ .......................... 68 
APPENDIX  2. PATIENT HEALTH QUESTIONAIRE -8 (PHQ -8) ................................ .......69 
APPENDIX  3. PATIENT  HEALTH QUESTIONNAIRE DEPRESSION SCALE 
(MODIFIED PHQ -A) ................................ ................................ ...................... 70 
APPENDIX  4. CHILDREN’S DEPRESSION INVENTORY 2 (PARENT REPORT)  .......... 71 
APPENDIX  5. COLUMBIA -SUICIDE SEVERITY RATING SCALE (C -SSRS) 
“BASELINE/SCREENING” VERSION  ................................ ......................... 72 
APPENDIX  6. COLUMBIA -SUICIDE SEVERITY RATING SCALE (C -SSRS) 
“SINCE LAST VISIT” VERSION  ................................ ................................ ..75 
APPENDIX  7. VALIDATED INVESTIGATOR GLOBAL ASSESSMENT SCALE 
FOR ATOPIC DERMATITIS  ................................ ................................ ......... 78 
Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 7 of 95 APPENDIX  8. DERMATOLOGY LIFE QUALITY INDEX  ................................ .................. 79 
APPENDIX  9. CHILDREN’S DERMATOLOGY LIF E QUALITY INDEX  ......................... [ADDRESS_140517] QUESTIONNAIRE  (DFI )  ..................... 83 
APPENDIX  11. SCORAD  ................................ ................................ ................................ .......... 85 
APPENDIX  12. PATIENT -ORIENTED ECZEMA MEASURE (POEM)  ................................ [ADDRESS_140518] OF TABLES  
Table 1.  ARQ -151-101: Skin Toleration Treatment -Emergent Adverse Experiences  ..... Error! 
Bookmark not defined.  
Table 2.      Excluded Medication s………………………………………………    ……………..3 8 
Table 3.      Laboratory Tests…………………………………………………………………….[ADDRESS_140519] OF FIGURES  
Figure 1. Contraception Requirements for Female Subjects  ................................ ....................  44 
 
 
 
  
Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 8 of 95 ABBREVIATIONS  
Abbreviation  Definition  
α Alpha Level (s ignificance level) 
AE Adverse Event  
AMP  Adenosine Monophosphate  
AD Atopic Dermatitis    
AUC  Area Under the Curve  
BSA  Body Surface Area  
CDI Children’s Depression Inventory  
CDLQI  Children’s Dermatology Life Quality Index  
Cmax Maximum Concentration  
cm Centimeter  
COPD  Chronic Obstructive Pulmonary Disease  
CRF  Case Report Form  
C-SSRS  Columbia -Suicide Severity Rating Scale  
CTCAE  Common Terminology Criteria for Adverse Events  
DFI Dermatitis Family Impact  
DNA  Deoxyribonucleic Acid  
DLQI  Dermatology Life Quality Index  
EASI  Eczema  Area and Severity Index  
FDA  U.S. Food and Drug Administration  
FOCBP  Female of Child Bearing Potential  
FSH Follicle -Stimulating Hormone  
GCP  Good Clinical Practices  
GLP  Good Laboratory Practices  
hr Hour  
IB Investigational Brochure  
IC50 Half Maximal Inhibitory Concentration  
ICF Informed Consent Form  
ICH  International Conference on Harmonisation  
ID Identification  
IGA Investigator Global Assessment  
IL Interleukin  
Protocol ARQ -151-[ADDRESS_140520]  
ITT Intent to Treat  
IWRS  Interactive Web Response System  
kg Kilogram  
LED  Light Emitting Device  
g Microgram  
MedDRA  Medical Dictionary for Regulatory Activities  
Mg Milligram  
min Minute  
mL Milliliter  
MTD  Maximum Tolerated Dose  
NCI National Cancer Institute  
NIH National Institutes of Health  
NOAEL  No Observed Adverse Effect Level  
ng Nanogram  
P-450 Cytochrome P450  
PDE -4 Phosphodiesterase 4  
PHQ -8 Patient Health Questionnaire -8 
PI [INVESTIGATOR_125027] -Oriented Eczema Measure  
QD Once Daily ("quaque die")  
SAE  Serious Adverse Event  
SAP Statistical Analysis Plan  
SCORAD  Scoring Atopic Dermatitis  
SD Standard Deviation  
S[LOCATION_003]R  Suspected Unexpected Serious Adverse Reaction  
TCPS  Tri-Council Policy Statement  
TEAE  Treatment Emergent Adverse Event  
Tmax Time to Reach Maximum Concentration  
Protocol ARQ -151-[ADDRESS_140521] Itch - Numeric Rating Score  
  
Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 11 of 95 1. PROTOCOL SUMMARY  
1.1. Synopsis  
 
Protocol Title:  A Phase 3, 4 -Week, Parallel Group, Double Blind, Vehicle -
Controlled Study of the Safety and Efficacy of ARQ -151 Cream 
0.15% Administered QD in Subjects with Atopic Dermatitis  
Clinical Indication:  Atopic Dermatitis  
Investigational 
Product : • ARQ -151 will be supplied as an emollient cream at 0.15%  
strength  
• Matching vehicle cream will contain only excipi[INVESTIGATOR_78414] -
151  
Study Design:  This is a Phase 3, parallel group, double blind, vehicle -controlled 
study in which ARQ -151 cream 0.15% or vehicle is applied QD  for [ADDRESS_140522] ≥3% BSA involvement (excluding the 
scalp,  palms, soles ) and mild or moderate atopic dermatitis (AD) 
based on vIGA -AD assessment.   
Upon determination of eligibility, subjects will be randomized 2:1 to 
either ARQ -151 cream 0.15% cream or matching vehicle cream.  
The randomization will be stratified by [CONTACT_26469] -AD score at 
Baseline /Day 1 (‘Mild’ vs. ‘Moderate’) and by [CONTACT_3885].  
Subjects/caregivers will apply  ARQ -151 cream 0.15% or vehicle 
cream QD for 28 days to all AD a ffected areas and any newly 
appearing AD lesions that arise during the study, except on the scalp . 
Subjects/caregivers should maintain treatment of these areas with 
study drug for the duration of the study regardless of whether 
treatable areas of AD clear prior to Week 4 /Day29 . 
At the Week 4 visit, subjects may be eligible to enroll in a 12‑month, 
open label extension study (ARQ -151-313) evaluating ARQ -151 
cream 0.15% QD.   
Study Objective:  To assess the safety and efficacy of ARQ -151 cream 0.15% vs 
vehicle administered QD x 4 weeks to individuals with atopic 
dermatitis.  
Study Sites:  Approximately 40  sites in the US and Canada . 
Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 12 of 95 Study Population:  Subjects will be male and female children and adolescents 
(6‑17  years), and adults ( >18 years). Subjects will have mild to 
moderate atopic dermatitis involvement with a vIGA -AD score of ‘2’ 
(Mild) or ‘3’ ( Moderate) for study entry. Up to 25% of the subjects 
will be ≥18 years old. Approximately 650 subjects are planned to be 
randomized  in this study.  
Duration of 
Participation for 
Subjects:  Screening (up to 30 days ) + Treatment phase (4 weeks) for a total of  
about 8 weeks.  
Upon completion of the treatment phase of the study (Week 4 /Day 
29) subjects may have the opportunity, subject to regulatory approval  
and enrollment has not been completed , to participate in an open -
label extension study (ARQ‑151 -313) of up to 12 months.  
Inclusion Criteria  1. For adult subjects: Participants legally competent to sign and 
give informed consent .  For pediatric and adolescent subjects: 
Informed consent of parent(s) or legal guardian, a nd, if age 
appropriate, assent by [CONTACT_748], as required by [CONTACT_1207].  
2. Males and females,  ages 6 years and older at time of signing 
Informed Consent (Screening) . 
3. Diagn osed with mild to moderate a topic dermatitis according to 
the criteria of Hanifin and Rajka (1980) prior to or at the 
screening visit .  Subjects must have at least 3 of the 4 basic 
features per Hanifin and Rajka (1. Pruritus; 2. Typi[INVESTIGATOR_125028] [flexural lichenification in adults 
and facial and extensor eruptions in infants and children]; 
3. Chronic or chronically relapsing dermatitis; or 4. Personal or 
family history of atopy), in addition to [ADDRESS_140523] 3 months in subjects 6 -17 years of age 
or 6 months in subjects >[ADDRESS_140524]’s medical chart, 
from the subject’s physician, or through  subject /parent/caregiver  
interview. Sta ble disease for the past 4 weeks with no significant 
flares in atopic dermatitis before screening.  
5. EASI Score >5.  EASI is evaluated for the entire body except the 
scalp, palms, and soles.  
6. vIGA -AD score of ‘Mild’ (‘2’) of ‘Moderate’ (‘3’) at Baseline. 
The vIGA -AD is evaluated for the entire body except the scalp, 
palms, and soles.  
7. Has AD involvement of >3% BSA (excluding the scalp, palms, 
soles).  
Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 13 of 95 8. Females of childbearing potential (FOCBP) must have a negative 
serum pregnancy test at Screening and a negative urine 
pregnancy test at Baseline /Day [ADDRESS_140525] 12  months (post -menopausal status should be confirmed 
with FSH testing) or have undergone surgical sterilization 
(permanent sterilization methods include hysterectomy, bilateral 
oophorectomy, hysteroscopic sterilization, bil ateral tubal ligation 
or bilateral salpi[INVESTIGATOR_1656]).  
10. In good health as judged by [CONTACT_737], based on medical 
history, physical examination, vital signs, serum chemistry labs, 
hematology values, and urinalysis . 
11. Subjects and parent(s)/legal guardian(s) are considered reliable 
and capable of adhering to the Protocol and visit schedule, 
according to the judgment of the Investigator.  
Exclusion Criteria  1. Subjects with any serious medical condition or clinically 
significant  laboratory, vital signs, or physical examination 
abnormality that would prevent study participation or place the 
subject at significant risk, as judged by [CONTACT_737]  
2. Liver  function  tests excursions that exceed:  
• AST or ALT > 2X ULN  
• Total bilirubin:  
− > 1.[ADDRESS_140526] or  
− > ULN and ≤ 1.[ADDRESS_140527] bilirubin is 
> 35% of total bilirubin  
• ALP ≥ 2x ULN  
3. Subjects who cannot discontinue medications and t reatment s 
prior to the Baseline visit an d during the study according to 
Excluded Medications and Treatments ( Table 2 Excluded 
Medications and Treatments ). 
4. Has unstable AD or any consistent requirement for high potency 
topi[INVESTIGATOR_125029].  
Protocol ARQ -151-[ADDRESS_140528] significant active systemic or localized 
infection  (e.g., molluscum contagiosum) , including known 
actively infected AD, or have had any infection that required oral 
or intravenous administration of  antibiotics, antifungal or 
antiviral agents within 14 days prior to Baseline /Day 1 . 
6. Subjects who are unwilling to refrain from prolonged sun 
exposure and from using a tanning bed or other artificial light 
emitting devices (LEDs) for 4 weeks prior to Basel ine/Day [ADDRESS_140529] of the study medication on AD, as 
determined by [CONTACT_737].  Subjects with any condition  on 
the treatment area which, in t he opi[INVESTIGATOR_689], 
could confo und efficacy measurements , e.g., molluscum 
contagiosum . 
8. Subjects with known genetic dermatological conditions that 
overlap with AD, such as Netherton syndrome . 
9. Known allergies to excipi[INVESTIGATOR_78413] -151 cream  
 
 
  
10. Subjects who cannot discontinue the use of strong cytochrome  P-
450 CYP3A4  inhib itors e.g.,  indinavir, nelfinavir, ritonavir, 
clarithromycin, itraconazole, ketoconazole, nefazodone, 
saquinavir, suboxone and telithromycin for 2 weeks prior to 
Baseline/Day 1  and during the study period.  
11. Subjects who cannot discontinue the use of strong  cytochrome P-
450 CYP3A4  inducers e.g., efavirenz, nevirapi[INVESTIGATOR_050], 
glucocorticoids, barbiturates (including phenobarbital), 
phenytoin, rifampin , and carbamazepi[INVESTIGATOR_114926] 2 weeks prior to 
Baseline/ Day [ADDRESS_140530] (Daxas®, 
Daliresp®) within  4 weeks prior to Baseline/ Day 1 . 
13. Known or suspected:  
• Severe renal insufficiency  
− Severe renal insufficiency is defined as calculated 
creatinine clearance <30 mL/min.    
• Moderate to severe hepatic disorde rs (Child -Pugh B or C)  
14. History of severe depression, suicidal ideation  or behavior , 
Baseline/Screening C -SSRS (for adolescents and adults 12 years 

Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 15 of 95 old and older) indicative of suicidal ideation  or behavior , 
whether lifetime or recent/current . 
15. Subjects with  a PHQ -8 (adults) or  modified PHQ -A 
(adolescents , 12-17 years old inclusive ) score  ≥10 at Screening 
or Baseline /Day 1  visits . 
16. Subjects (6 to 11 years old, inclusive) with a CDI -2 (parent 
report) raw score ≥17 for females and ≥18 for males  at Screening  
or Baseline /Day [ADDRESS_140531] -feeding . 
18. Previous t reatment with ARQ -151. 
19. Subjects currently undergoing allergy  testing  (e.g., food allergy 
testing or skin prick testing), patch testing, food challenges, or 
allergy desensitization, or plan to do so during the study.  
20. Subjects with any serious medical condit ion (e.g., hypo - or 
hyper -thyroidism)  or clinically significant laboratory 
abnormality that would prevent study participation or place the 
subjec t at significant risk, as determined by [CONTACT_941] I nvestigator . 
21. Subjects with a history of a major surgery within 4 weeks prior 
to Baseline /Day [ADDRESS_140532] a major surgery planned 
during the study.  
22. Subjects with a history of chronic alcohol or drug abuse within 
6 months prior to Screening . 
23. Current or a histo ry of cancer within 5 years with the exception 
of fully treated  skin basal cell carcinoma, cutaneous squamous 
cell carcinoma or carcinoma in situ of the cervix.   
24. Parent(s)/legal guardian(s) who are unable to communicate, read, 
or understand the local langu age(s).  Subjects who are unable to 
communicate, read or understand the local language, or who 
display another condition, which in the Investigator’s opi[INVESTIGATOR_1649], 
makes them unsuitable for clinical study p articipation.  
25. Subjects who are family members of the cl inical study site, 
clinical study staff, or sponsor, or family members of enrolled 
subjects  living in the same house.  
Key Assessments:  Safety Assessments  
• Safety will be monitored through local tolerability 
assessments, vital signs, physical examination, safety labs, 
Children's Depression Inventory 2 (CDI -2, parent report for 
children 6 -11 years old, inclusive ), modified PHQ -A (for 
adolescents 12 -17 years ol d, inclusive), PHQ -8 (for adults), 
Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 16 of 95 C-SSRS (for adolescents  and adults 12 years old and older ), 
and AEs.  
• After obtaining consent, all AEs and TEAEs should be 
collected.  
• The investigator or a properly trained and designated 
subinvestigator will perform loc al tolerability assessments  at 
Baseline /Day 1 , and weeks 1, 2, and 4 ( Days  8, 15, and 29). 
Subjects will have vital signs measured at each study visit. 
Height will be collected at Visit 1(Screeni ng) only.  
• A limited physical exam (skin, lungs, and heart onl y) will be 
performed at Screening, Baseline /Day 1  and Week 4 /Day 29 . 
Blood and urine samples for routine safety laboratory tests 
(hematology, serum chemistry, and urinalysis) will be 
obtained at Screening, Baseline /Day 1  and Week 4 /Day [ADDRESS_140533] will be 
perfo rmed. A negative pregnancy result is required for 
continued participation in the s tudy, and r esults (of the urine 
pregnancy test) must be available prior to dispensing of study 
drug at study visits.   
Efficacy Assessments  
• Efficacy  assessments will include vIGA -AD (Appendix  2), 
EASI , WI-NRS, BSA  (Appendix 1) , DLQI/ CDLQI   
(Appendix 8 and 9) , DFI (Appendix 10) , SCORAD 
(Appendix  4), and POEM  (Appendix  6). 
Pharmacokinetic Assessment  
• A single PK assessment  (trough) will be performed in all 
subjects with a blood sample collected at Week 4/Day 29 . 
Study Endpoints  1. The Primary Efficacy Endpoint wi ll be tested in all 
randomized subjects and defined as:  
• The proportion of all randomized subjects who attain IGA 
Success, defined as a vIGA -AD score of ‘clear’ or ‘almost 
clear’ PLUS a [ADDRESS_140534] the 
Secondary Efficacy Endpoint s defined as:  
Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 17 of 95 • The proportion of randomized subjects with a vIGA -AD 
score of ‘Moderate’ at randomization who attain IGA 
Success  at Week 4  
• Among subjects with baseline WINRS  4, the proportion 
who attain a 4‑point reduction on the WI -NRS  at week 4  
• The proportion of subje cts who attain at least a 75% 
reduction in the Eczema Area and Severity Index ( EASI -
75) at Week 4  
• Time to achievement of  vIGA -AD success  
• Time to achievement of EASI -[ADDRESS_140535] the key secondary endpoint of IGA success in subjects 
with a vIGA -AD score of ‘Moderate’ at randomization, 
approximately [ADDRESS_140536] vIGA‑AD 
score of ‘Moderate’ at randomization.  Randomization will be 
stratified by [CONTACT_26469] -AD score (‘Mild’ vs. ‘Moderate’) and by [CONTACT_106100]. 
This sample size provides approximately 95% power to detect an 
overall 15% difference between  treatment groups on vIGA‑AD 
success at week 4 at α-0.05 using a 2 -sided stratified (vIGA -AD at 
randomization and study site ) Cochran -Mantel -Haenszel test .  The 
results from a recent phase 2 study (ARQ ‑151-212) of ARQ -151 
cream 0.15% compared to vehicle tr eatment were used to estimate 
the treatment difference.  Specifically, in the phase 2  trial, 
approximately 37 % of subjects demonstrated vIGA -AD success at 
week 4  in the ARQ -151 0. 15% group compared to  22% in the 
vehicle group.   This sample size also provid es approximately 90% 
power to detect an overall 17% difference between treatment groups 
on IGA success at week 4 among subjects with vIGA -AD score 
‘Moderate’ at randomization. The same testing method, the stratified 
Cochran -Mantel -Haenszel test, will be us ed as for the primary 
endpoint.  
Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 18 of 95 Statistical Analysis:  The analysis populations are defined as follows:  
• Safety population will include all subjects who are enrolled 
and received at least one confirmed dose of study medication.  
• Intent -to-Treat (ITT) population will include all subjects who 
are randomized.  
• vIGA -AD Moderate ITT population will be a subset of the ITT 
population with vIGA -AD score ‘moderate’ at randomization . 
• WI-NRS population will be a subset of the ITT population 
with a baseline WI -NRS score  4. 
• PK population will include all subjects receiving the active 
drug with quantifiable plasma concentrations of roflumilast.   
To control for multiple comparisons, the key secondary endpoint will 
only be tested if the primary endpoint demonstrates statistical 
significance.  In addition, the remaining secondary endpoints will be 
inferentially tested only if the primary and key secondary endpoint 
comparisons are statistically significant.  To control for multiple 
comparisons amon g the remaining secondary endpoints, partitioning 
of alpha and the Holm’s procedure will be used.  
Descriptive statistics for continuous variables will include mean, 
median, standard deviation, min, max. Descriptive statistics for 
categorical variables will  include frequencies and percents. For 
missing data, the primary imputation method and sensitivity methods 
will be detailed in the SAP. The primary endpoint and key secondary 
endpoint s of vIGA -AD success  will be analyzed with a Cochran -
Mantel -Haenszel test  stratified by [CONTACT_125060]  (disease 
severity determined by [CONTACT_26469] -AD and by [CONTACT_3885]) . 
Categorical  secondary efficacy analysis will be analyzed in the same 
manner as the primary endpoint.   
Continuous secondary endpoints will be analyzed analysis of 
covariance with treatment, the randomization stratification factors, 
and baseline value as independent v ariables .  Statistical comparisons 
between the treatment groups will be obtained using contrasts.  
The incidence of adverse events will be summarized as well as 
changes in laboratory parameters and vital signs.  
  
Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 19 of 95 1.2.  Study  Schema  
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Screening  
 
ARQ -151 
0.15%  Matching 
Vehicle Cream  
Treatment Period and Clinic Visits  
Week 1/Day 8, Week 2/Day 15, and Week 4/Day 29  
 Randomization and Treatment  
Baseline / Day 1  
(N=650)  
Not Participating in Open 
Label Extension Study  
 
End of Study  
 
 
 
 
 
  Participating in Open Label 
Extension Study  
 
ARQ -151-313 
 
Enrollment  
 
 
 
  A Phase 3, 4 -Week, Parallel Group, Double Blind, Vehicle -Controlled Study of 
the Safety and Efficacy of ARQ -151 Cream 0.15% Administered QD in 
Subjects with Atopic Dematitis  
 
Approximately 650 subjects with atopic dermatitis  will be randomized 2:1 to rece ive 
either:  
• ARQ -151 cream 0.15%  or Vehicle cream  
Subjects will have ≥3% BSA involvement (excluding the scalp,  palms, soles ) with a 
vIGA -AD score of ‘2’ (mild) or ‘3’ (moderate) for study entry  
Up to 25% of the subjects will be ≥ 18 years old  
Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 20 of 95 1.3. Schedule of Visits and Assessments  
Study Procedure  Screen  Baseline  
Day 1  Wk 1  
Day 8  Wk 2  
Day 15  Wk 4  
Day 29  / ET 
Visit  1 2 3 4 5 
Visit Window  -30 days  N/A +/- 3 days  +/- 3 days  +/- 3 days  
Informed consent /assent  X     
Demographics  X     
Medical and surgical 
history  X     
Physical examinationa X X   X 
I/E criteria  X X    
Hematology, Serum 
Chemistries, and Urine 
Analysisb X X    
X 
Vital signs, height, weightc X X X X X 
vIGA -AD, EASI, BSA, 
SCORADd X X X X X 
WI-NRS prurituse X X X X X 
POEMf X X X X X 
Local Tolerability 
Assessmentg   X X X X 
CDI-2, PHQ -8, PHQ -A, 
C‑SSRSh X X X X X 
DLQI, CDLQI, DFIi X X X X X 
Medical Photographyj  X X  X 
Serum pregnancy test  
(FOCBP only ) X     
Urine pregnancy testk  X X X X 
PK drawsl     X 
Drug/vehicle application 
in clinicm  X X X  
Dispense /Re-dispense  study 
medication kitn  X Xo Xo Xo 
Dispense/review diary   X X X X 
Weigh study medication 
kitp  X X X X 
Compliance 
determinationq   X X X 
Adverse event assessmentr X X X X X 
Concomitant medications  X X X X X 
Study Exit s     X 
 
Footnotes from table above:  
Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 21 of 95 a Limited physical examination: skin  (including assessment of Fitzpatrick skin type  at Screening only ), lungs, and 
heart only  
b To be collected at Screening, Baseline /Day 1 , and Week 4 /Day  29. For subjects <18 years of age, if Baseline /Day 
[ADDRESS_140537] should remove shoes and 
heavy clothing (sweaters or jackets), and empty pockets. The subject should stand with both feet in the center of 
the scale with their arms at their side and hold still . Record the weight to the nearest decimal fraction (for example, 
25.1 kilograms). For subjects <18 years of age, measure the weight in triplicate  and report the average weight in 
EDC. A 5% or greater weight loss (whether or not intentional or other explained ) should be reported to the 
medical monitor.  
d The vIGA -AD assessment will be a 5 -point scale ranging from clear (0) to severe (4) and is evaluated for the 
entire body except the scalp, palms, and soles. EASI takes into accoun t overall severity of erythema, 
infiltration/papulation, excoriation, and lichenification, in addition to extent of BSA affected. The 4 clinical signs 
will be graded on a 4 -point scale (0 [absent] to 3 [severe]) for 4 body regions (head and neck, upper ext remities, 
lower extremities, and trunk). Total EASI score will be calculated as a sum of scores of all 4 body regions. EASI 
total score will range from 0 (absent) to 72 (severe). Total BSA affected by [CONTACT_125061], palms and soles. The vIGA -AD assessment should be completed prior to other 
physician assessments . SCORAD total score will range between 0 and 83.  
e Subjects will self -assess their pruritus at home on a daily basis  starting 7 days prior to the Basel ine/Day [ADDRESS_140538] 24 
hours. The scale is from 0  (no itch)  to 10 (worst itch)  and this value will be recorded by [CONTACT_125062] . 
f POEM w ill be completed by [CONTACT_125063]  (for children unable to read and/or 
understand the POEM questionnaire, the parent/guardian/caregiver will complete the questionnaire) . 
g Local tolerability assessments should be recorded prior to study drug application for the Investigator assessment of 
skin irritation (Berger and Bowman skin irritation score) . Note for investigator tolerability assessments: 
reactions at the site of product application, which may occur post -Baseli ne, should be differentiated from 
the preexisting inflammation associated with the  subject’s atopic dermatitis.  The subject will assess 
burning/stinging (0 -3 score) [ADDRESS_140539] burning stinging assessment : at 
Day 29, s ubjects will provide a recall assessment of burning/stinging experienced post drug application on 
the previous day ( Day 28).  
h Adolescents and adults will complete the C -SSRS  (12 years of age and older) .  Adults will complete the PHQ -8.  
Adolescents  (ages 12 to 17, inclusive)  will complete the PHQ -A (PHQ -9 modified). Parents /caregivers  will 
complete CDI -2 (parent report) for children 6-11 years of age , inclusive . 
i The DLQI wi ll be completed by [CONTACT_1766] ≥[ADDRESS_140540] Questionnaire (DFI) will be completed by [CONTACT_3654]/caregivers 
for all subjects 6 to ≤17 years of age.  
j Photogr aphy of AD lesion(s) selected by [CONTACT_125064].  All efforts 
will be made to de -identify the subjects. Canfield equipment will be used to capture photographs.  Subjects who are 
unwilling to participate in th e medical photography will be allowed to opt out of this procedure , as documented on 
the Informed Consent Form . 
kA urine pregnancy test will be administered to all females of child -bearing potential. A negative result is required 
for continued participati on in the study, and results must be available prior to dispensing of study drug at each 
visit.  
l Single PK trough draw will be collected at Day 29. Ensure study medication  was not applied in the area where PK 
will be drawn.  
m Subjects to apply assigned IP during  clinic visits , except for the Day 29 visit . 
n Kits will be dispensed based on %BSA affected. See IP Handling Manual for details.   
o On Day [ADDRESS_140541] is unable to perform  the Day 29 
clinic visit due to COVID -19 restricti ons (isolation, quarantine, etc.) then additional IP may need to be dispensed 
so IP can continue to be applied at home until the subject is able to return to the clinic to complete the Day 29 
assessments (see IP Handling Manual for the process to dispense additional IP at or after Day 29).  
p Every tube should be weighed and recorded when dispensed and returned. . See IP Handling Manual for details.  
q Compliance determination  is described in the IP Handling Manual  
Protocol ARQ -151-[ADDRESS_140542] or the e nd of the study (whichever is later). Any AEs 
(whether serious or non -serious) and clinically abnormal laboratory test values(s) will be evaluated by [CONTACT_978] [INVESTIGATOR_125030]/or followed up for up to 30 days after end of treatment or until symptoms or value( s) return to normal, 
or acceptable level, as judged by [CONTACT_978]  
s Subjects who enroll into the open label extension study (ARQ -151-313) must  complete the ARQ -151-[ADDRESS_140543] is a phosphodiesterase 4 (PDE-4) inhibitor approved globally  to reduce the risk of  
exacerbations in patients with severe chronic obstructive pulmonary disease ( COPD ) associated 
with chronic bronchitis.  Roflumilast and its active metabolite, roflumilast N -oxide , are high 
affinity selective inhibitors of PDE -4 (a major cyclic -3′,5′-adenosine monophosphate 
(cyclic  AMP) -metabolizing enzyme), whose activity leads to accumulation of intracellular cyclic 
AMP.  There are four different subtypes  of PDE -4: PDE -4a, PDE -4b, PDE -4c, and PDE -4d, each 
with several isoforms (splicing variants) .  IC [ADDRESS_140544] N -oxide 
for the different PDE -4 isoforms and subtypes are mostly sub -nanomolar and single digit 
nanomolar (Hatzelmann 2010 ).  The PDE -[ADDRESS_140545] was initially developed as a 500 g tablet for oral therapy in patients with COPD,  
and as such has been thoroughly evaluated in nonclinical studies.  The safety profile is 
well-established.  Oral roflumilast (500 g tablet) was approved by [CONTACT_125065]® 
in December 2010 and by [CONTACT_78445]® in February  [ADDRESS_140546] is applied 
dermally.  
The dermal nonclinical program for ARQ -151 cream followed current In ternational Conference 
on Harmonisation (ICH) guidelines  and includes a 13 -week dermal toxicity study in minipi[INVESTIGATOR_14107], a 
13-week dermal toxicity study in mice, a 39 -week dermal toxicity study in minipi[INVESTIGATOR_14107], a skin 
sensitization study in guinea pi[INVESTIGATOR_14107], a phototoxic ity study, an eye irritation study and a 104 -week 
carcinogenicity study in mice , the in life portion of which is complete . 
Refer to the current ARQ -151 I nvestigator’s Brochure (IB) for the most current PDE -4 dermal 
and oral/systemic nonclinical and clinica l information.   
Atopic dermatitis is a chronic  inflammatory skin disorder af fecting children and adults, with the 
majority presenting with disease of mild to moderate severity.  The use o f topi[INVESTIGATOR_12870]/or topi[INVESTIGATOR_22726], in combination with emollients has been the mainstay for 
treating atopic dermatitis.  In 2016, Eucrisa® (crisaborole), a PDE -4 inhibitor was approved for 
the topi[INVESTIGATOR_125031] 2 years of age and older .   
Topi[INVESTIGATOR_19529] l calcineurin inhibitors block the activation of T -lymphocytes and diminish inflammation, 
but are accompanied by a boxed warning for the development of lymphomas and other 
lymphoproliferative diseases.  Topi[INVESTIGATOR_125032] -
pi[INVESTIGATOR_125033], and their use is of ten accompanied by [CONTACT_125066] (fear of using corticosteroids i n patients or doctors).  Eucrisa provides precedence 
for the effectiveness of topi[INVESTIGATOR_22732] -[ADDRESS_140547], and its use may be accompanied by [CONTACT_125067], stinging, and 
local skin reactions. As a result, there is a need for the development of new topi[INVESTIGATOR_125034] (Nygaard  2017 ). 
The therapeu tic use of PDE -4 inhibitors in AD is based on the recognized intracellular role of 
PDE -4 in keratinocytes (Dastidar  2007 , Hanifin  1996 ). Circulating leukocytes in AD patients 
Protocol ARQ -151-[ADDRESS_140548] PDE -4 activity, which has been associated with higher production of proinflammatory 
mediators and lower production of the anti -inflammatory mediator IL -10, in part due to 
hydrolyzation of cyclic adenosine monophosphate (cAMP)  (Grewe  1982 , Furue  2014 , 
Baumer  2007 ).  This consequently diminishes levels of cAMP, which leads to increased 
transcription of numerous cytokines, accelerating a number of intracellular functions involved in 
acute and chronic inflammation (Grewe  1982 ).  Thus, targeting PDE -4 has been shown to 
directly attenuate inflammation due to inhibition of the breakdo wn of cAMP, consequently 
reducing the levels of tumour necrosis factor -α, IL -12, IL -23, and other signaling effectors  
(Murrell  2015 , Nazarian  2009 ). 
2.2. Conclusions on Toxicity Findings  
The safety profile of o ral roflumilast is well -established.   An extensive systemic toxicity program 
that evaluated both roflumilast and its active N -oxide metabolite in multiple species via the oral 
route of administration was conducted to support registration  of the  [ADDRESS_140549] been identified through the dermal 
toxicity program.   In 13 -week dermal toxicity studies in minipi[INVESTIGATOR_125035],  and a 39-week 
dermal toxicity study in minipi[INVESTIGATOR_14107],  no evidence of systemic toxicity was observed.   
Histopathological evaluation of skin in the minipig study included very slight to slight erythema 
at all treatment levels, and minor degrees of irritation such as hype rplasia.   The NOAEL in both 
studies was the 1% concentration of ARQ -151 (20  mg/kg), the highest dose administered and the 
maximum feasible concentration.  
Across the dermal and systemic toxicology programs, the exposure to parent drug and N -oxide 
metabolite  differs by [CONTACT_125068] . While exposure to roflumilast and its active metabolite 
are likely to be higher following topi[INVESTIGATOR_125036] -[ADDRESS_140550], ARQ -151 cream, has been evaluated in both plaque 
psoriasis ( currently in  Phase 3) and atopic dermatitis (through Phase 2).  
2.3.2.  Psoriasis Phase 2a  (ARQ -151-101) 
 
ARQ -151-101 ([STUDY_ID_REMOVED] ) was a Phase 2a study of two active doses of ARQ -151, 0.5% and 
0.15% vs vehicle in the topi[INVESTIGATOR_125037] 
5% BSA involvement .  
Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 25 of 95 An initial cohort (Cohort 1) of 8 adult psoriasis subjects (no vehicle subjects) was treated as 
follows with the results indicated:  
• Single dose application of ARQ -151 cream 0.5% to a 25 cm2 area o f psoriatic plaque on 
the trunk or extremities (not on the face, genital area, palms or soles)  
• Local tolerability and systemic safety labs monitored  
• PK assessments at baseline (pre -dose), 1, 2, 4, 6 and 24 hours  
• Skin permeation of topi[INVESTIGATOR_125038] w as ~0.4%  
• Local tolerability and systemic safety labs were unremarkable  
Six Cohort [ADDRESS_140551] (0.15% and 0.5%) versus vehicle applied QD  x 28 days, analyzing t arget 
psoriatic plaques for efficacy.  Subjects were randomized 1:1 :1 to receive 0.5% drug product , 
0.15% drug product  or vehicle to psoriatic plaques  up to 5.0% of  BSA .  In each subject, up to 
3 target plaques were  identified for efficacy analys is. 
PK assessments conducted on day 1: 1, 2, 4 and 6 hours; day 14: pre -dose (trough) and [ADDRESS_140552]-dose; and day 28: pre -dose (trough), 1, 2, 4, 6 and 24 hours . 
Safety res ults follow:  
•  
 
  
 
 
  
  
  
   
  
   
  
  
  
 
     
 
     
      
      
      
      
      

Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 26 of 95 •  
 
  
  
 
 
 
 
 
 
  
  
Day 28 pharmacokinetic results of ARQ -151-101 are as follows:  
 
• Following 28 days of ARQ -151 cream 0 .5% and 0.15% application to a mean BSA% 
 
 
 
  
 
  
 
 
2.3.3.  Psoriasi s Phase 2b  (ARQ -151-201) 
 
ARQ -151-201 ( [STUDY_ID_REMOVED] ) was a parallel group, double blind, vehicle -controlled study in 
which ARQ -151 cream 0. 15%, ARQ -151 cream 0. 3%, or vehicle cream wa s applied QD for 12 
weeks  to over 300 adult subjects  with 2% to 20% BSA  of chronic plaque psoriasis and baseline 
IGA of Mild or greater.   In this study, both ARQ -151 cream 0.3% and ARQ -151 cream 0.15% 
were safe and well tolerated, demonstrating similar safety and tolerability profiles compared to 
each other and compared t o vehicle.  The safety data are summarized below : 
•  
 
 
 
 
 
  
  
 
  

Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 27 of 95  
  
  
 
  
 
 
 
 
  
 
 
 
 
 
  
 
  
 
 
  
 
 
 
 
  
 
 
Pharmacokinetic results of ARQ -151-201 are as follows:  
•  
 
 
  
  
 
  
 
 

Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 28 of 95 •  
  
 
2.3.4.  Atopic Dermatitis Phase 1 PK Study  in Adults (ARQ -151-102) 
 
ARQ -151-102 was an open label, Phase 1, pharmacokinetics and safety study of ARQ -151 
Cream 0.15% and ARQ -151 Cream 0.05% administered QD in adult subjects with mild to 
moderate AD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
2.3.5.  Phase 1 Study  in Adolescents and Pediatrics ( ARQ -151-105) 
 
ARQ -151-105 ([STUDY_ID_REMOVED]) is an ongoing o pen-label, Phase 1, pharmacokinetics , maximal 
usage PK, s afety,  and efficacy s tudy of ARQ -151 cream 0.15% a dministered QD in adolescent 
and p ediatric subjects with mild to moderate atopic dermatitis .   
The study is being conducted in three parts, the first two of which are completed.  The first part 
consisted of three cohorts in which  subjects  aged 2 to 17 years old  had 1.5-35% BSA 
involvement (excluding the scalp,  palms, soles ) and mild or moderate atopic dermatitis  based on 
vIGA -AD.   
The second part of the study consisted  of three cohorts in which  subjects were evaluated under 
maximal use conditions  (MUSE)  and had BSA involvement ( excluding the scalp,  palms, soles ) 
of ≥35% in subjects 2 to 11 years old (inclusive) or ≥25% in subjects 12 to <[ADDRESS_140553] 60% of the enrolled subjects 
had moderate atopic dermatitis .  
The third part of the study will consist of one cohort (Cohort 7) in which  subjects 2 to 5 years of 
age (inclusive)  will be administered a lower concentration of ARQ -151 cream (0.05%) and 
evaluated under maximal use conditions  (MUSE) . Subjects will have BSA involvement 
(excluding the scalp,  palms, soles ) of ≥35% with mild or moderate atopic dermatitis  based on 
vIGA -AD. At least 60% of the enrolled subjects had moderate atopic dermatitis .   
Preliminary Study Results  
 
 
 
 
 
 
 
 
 
 
 
 
   
 
   
2.3.6.  Atopic Dermatitis  Phase 2 Dose Ranging Study ( ARQ -151-212) 
ARQ -151-212 ([STUDY_ID_REMOVED] ) was  a parallel group, double blind, vehicle -controlled, Phase 2 
study that evaluat ed ARQ -151 cream 0.05% and 0.15% in the treatment of mild to moderate 
atopic dermatitis  in 136 adolescent and adult subjects with 1.5 to 35%  BSA of involvement .   
Ninety -three  female (68.4%) and 43 male (31.6%) subject s with mild to moderate AD 
participated in the study. Overall, the demographic and baseline disease characteristics were 
similar across all study groups.  The mean age for all 136 study subjects was 41.6 years, 
including 8 adolescent subjects (between 12 -17 years). The mean EASI score at Baseline for all 
study subjects was 9.04. The majority of subjects were in the moderate vIGA -AD category 
(77.9%). The mean BSA involvement was 9.5% for all stud y subjects . 
 
 
 
 
 
 

Protocol ARQ -151-[ADDRESS_140554] (DALIRESP®) has been approved globally for the treatment of COPD and has 
been evaluated in nine Phase III/IV randomized double -blind clin ical trials  (Wedzicha 2016 ).  
Overall, the safety of oral roflumilast has been well established in its targeted population of 
mostly middle - and upper -aged individuals who currently smoke cigarettes or have smoked them 
extensively in the past.  Adverse events (AEs) reported with roflum ilast tablets have been 
consistent with those expected for oral PDE -4 inhibitors .  In a pooled analysis of safety data 
from 6 -month and 1 -year clinical trials (N=8630), the most common AEs were diarrhea, weight 
loss and nausea.  Other AEs reported more fre quently with roflumilast treatment than with 
placebo were back pain, influenza, insomnia and decreased appetite (Michalsk, 2012 ), 
(Wedzicha, 20 16).   
In addition to the self -reported cases of weight loss in the 6 -month and 1 -year oral trials, 
clinically significant weight loss was also reported in two prospective studies that evaluated 
weight  (Michalsk, 2012 ). 
Psychiatric -related AEs were also greater in patients treated with roflumilast tablets (5.9%) 
compared to those treated with placebo (3.3%).  The most common psychiatric -related AEs were 
insomnia, depression and anxiety.  A small n umber of cases of completed suicide and suicide 
ideation have been reported in patients taking oral roflumilast in clinicals trials and also during 
post-marketing experience  (Michalsk, 2012 ).   
The only contraindication to oral roflumilast  is use in patients with moderate to severe liver 
impairment (Child -Pugh B or C), where systemic levels of roflumilast may become elevated . 
2.4. Rationa le for Development  
Atopic dermatitis is currently treated with t opi[INVESTIGATOR_125039]/or topi[INVESTIGATOR_125040].  In 2016, Eucrisa® (crisaborole), a less potent 

Protocol ARQ -151-[ADDRESS_140555], was approved for the topi[INVESTIGATOR_22787].  
Topi[INVESTIGATOR_125041] T -lymphocytes and diminish inflammation, 
but are accompanied by a ‘black box’ warning for the development of lymphomas and other 
lymphoproliferative diseases.  Topi[INVESTIGATOR_125042]-
pi[INVESTIGATOR_125033], and their use is of ten accompanied by [CONTACT_125066] (fear of using corticosteroids i n patients or doctors).  Eucrisa provides precedence 
for the effectiveness of topi[INVESTIGATOR_22732] -[ADDRESS_140556], and its use is often accompanied by [CONTACT_125067], stinging, and local 
skin reactions.  In our Phase 2 AD study (ARQ -151-212), we observed excellent local toleration 
of ARQ -[ADDRESS_140557] is a more potent PDE -4 inhibitor than 
crisaborole  (Hatzelmann 2010 ), we believe that ARQ -151 has potential to provide greater 
efficacy with better local toleration than Eucrisa . 
This study will evaluate the safety and efficacy of ARQ -151 cream in children, adolescent, and 
adult subjects with mild to moderate atopic dermatitis.  
2.4.1.  Dose Selection  
In ARQ -151-212, results for the primary efficacy endpoint, mean absolute change from baseline 
in EASI score at Week 4, were numerically higher in the ARQ -151 cream 0.05% and ARQ -151 
cream 0.15% (p= 0.097) groups than in the vehicle group. Furthermore, the result of the 
sensitivity analysis of the primary endpoint at Week 4 was statistically significant (ARQ -151 
cream 0.15%, p= 0.027). Statistical significance was reached for numerous other clinically 
important efficacy endpoints including % change from base line in EASI score, EASI -[ADDRESS_140558] (0.15% and 0.05%) had a similar and favorable safety and tolerability profile, with 
generally more favorable efficacy o bserved at the ARQ -151 cream 0.15% dose. Results of this 
study support  the use of ARQ -151 cream  0.15% in studies of adult and adolescent subjects with 
mild to moderate AD. PK data from ARQ -151-105 support the use of the same concentration 
(0.15%) in subjec ts 6 to 11  years old and the use of a lower concentration in subjects 2 to 5 years 
old. 
2.4.2 Risks and/or Benefits to Subjects  
A favorable  local and systemic benefit -risk profile  has been  observed  in prior studies  of ARQ -
151. Subjects 6 years of age and older,  included in this study,  randomized to active treatment 
group may see an improvement in their atopic dermatitis with ARQ -151 0.15% cream, based on 
the activity of doses tested in atopic dermatitis (0.05% -0.15%) and psoriasis (0.15% -0.5%) , and 
approva l of a less potent topi[INVESTIGATOR_22732] -4 inhibitor (crisaborole) for atopic dermatitis.  Subjects 
may also see some benefit as the cream formulation of ARQ -[ADDRESS_140559] has been well -documented.  The known adverse effects of oral treatment in 
the COPD population (nausea, vomiting, diarrhea, weight loss, psychiatric AEs  (see 
Section  2.3.7 ) may be  readily monitor ed as specified i n this protocol . The profile that is 
emerging from studies of topi[INVESTIGATOR_125043].  While oral PDE -4 inhibitors (DALIRESP, OTEZLA) have been 
associated with, in particular, a mo derate incidence of GI AEs, these AEs, and perhaps others, 
Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 32 of 95 appear to be reported far less frequently with topi[INVESTIGATOR_22732] -4 inhibitors, including EUCRISA®, 
and ARQ -151 cream to date in clinical trials.  For ARQ -151 cream, this may be related to the 
lack of ‘pe ak to trough’ C max variation , lower C max values than observed following oral 
administration , or by[CONTACT_125069][INVESTIGATOR_78086] .  
This study has been designed with adequate  safety monitoring practices (i.e., physical 
examination s, vital signs/weight, local skin toleration  assessments, hematology, serum 
chemistry, urinalysis, PHQ -A/PHQ -8, CDI-2, C-SSRS and AE reporting ). 
3. STUDY OBJECTIVES  AND  ENDPOINTS  
3.1. Study Objectives  
3.1.1.  Primary Objective  
The primary object ive of this study is to  assess the safety and efficacy of ARQ -151 cream 0.15% 
vs vehicle administered QD x 4 weeks to individuals 6 years of age and older with atopic 
dermatitis.  
3.2. Study  Endpoints  
3.2.1.  Primary Endpoint  
The primary endpoint of this study is :  
• The pro portion of all randomize d subjects who attain IGA Success, defined as a 
vIGA -AD score of ‘clear’ or ‘almost clear’ PLUS a 2 -grade improvement from 
Baseline at Week  4 
3.2.2.  Secondary  Endpoint s 
The secondary endpoints of this study are : 
• The proportion of randomized subjects with a vIGA -AD score of ‘Moderate’ at 
randomization who attain IGA Success at Week 4  
• Among subjects with baseline WINRS  4, the proportion who attain a 4‑point 
reduction on the WI -NRS at week 4  
• The proportion of subje cts who attain at least a 75% reduction in the Eczema Area and 
Severity Index (EASI -75) at Week 4  
• Time to achievement of vIGA -AD success  
• Time to achievement of EASI -75 
3.2.3.  Pharmacokinetic Endpoint  
• Pharmacokinetic endpoints include concentrations of roflumilast  and its N -oxide 
metabolite.  
Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 33 of 95 4. INVESTIGATIONAL PLAN  
4.1. Overall Study Design and Plan  
This is a Phase 3, parallel group, double blind, vehicle -controlled study in which ARQ -151 
cream 0.15% or vehicle is applied QD x 4 weeks to subjects with mild to moderate atop ic 
dermatitis.  
• At entry, subjects  will have ≥3% BSA involvement (excluding the scalp,  palms, 
soles ) and mild or moderate atopic dermatitis (AD) based on vIGA -AD assessment.   
• Upon determination  of eligibility, subjects will be randomized 2:1 to either ARQ -151 
cream 0.15% or matching vehicle cream.  The randomization will be stratified by 
[CONTACT_26469] -AD score at baseline (‘Mild’ vs. ‘Moderate’)  and study site.  
• Subjects/ caregivers  will apply ARQ -151 cream 0.15% or vehicle cream QD for 
28 days to all AD affected areas and any newly appearing AD lesions that arise 
during the study, except on the scalp . Subjects/caregivers should maintain treatment 
of these ar eas with study drug for the duration of the study regardless of whether 
treatable ar eas of AD clear prior to Week 4.  
• At the Week 4 visit, subjects may be eligible to enroll in a 12‑month, open label 
extension study (ARQ -151-313) in which they will receive  ARQ -151 cream 0.15% 
QD.   
4.2. Number of Sites and  Subjects  
A total of up to approximately [ADDRESS_140560] of the study, additional countries and/or 
sites may be added if necessary . Subjects will be male and female children and adolescents 
(6‑17  years), and adults ( >18 years). Subjects will have mild to moderate atopic dermatitis 
involvement with a vIGA -AD score of ‘2’ (mild) or ‘3’ (moderate) for study entry. Up to 25% of 
the subjects will be ≥18 years old  and up to 25% of subjects will have a vIGA -AD score of ‘2’ . 
4.3. Subject Participation  
Subject participation involves a minimum of [ADDRESS_140561] participation  is 
approximately 8 weeks . 
Upon completion  of the treatment phase of the study (Week 4) subjects may have the 
opportunity, subject to regulatory approval  and enrollment has not been completed , to participate 
in an open -label extension study (ARQ‑151 -313) of up to [ADDRESS_140562] 
indentification (ID)  number  by [CONTACT_125070] .   
Protocol ARQ -151-[ADDRESS_140563]  identifier number is 6 -digits (SXX -YYY) and will contain the study number -site 
number ( where S = 1 and XX is this study site number such as 01, 02, etc. ) and the subject 
number (YYY). It will be assigned in numerical order at the screening visit based on 
chronological order of screening dates.  
Individuals  who do not meet the criteria for participation in this trial (screen failure) may be 
rescreened once, if deemed acceptable by [CONTACT_093]. Rescreened subjects should be 
assigned a different subject number than the initial screening. All procedures planned at the 
screening visit, including signature [CONTACT_4007] a new consent form, will be performed.   
In the case of a screening laboratory value abnormality, the test can be repeated once within the 
original screening time window, if the investigator believes there is a reasonable possibility that 
the subject would be eligible if re -tested. This would not be cons idered a screen failure  and a 
new subject number would not be assigned . 
The clinical site is responsible for maint aining a current log of subject ID number assigned to 
each subject. The subject ID number will be used to identify the subject throughout the study and 
is required to be entered on  all clinical study documentation (e.g., case report forms, labeling of 
clinical materials and sample  containers, investigational product accountability logs, etc.).   
4.5. Selection of Study Population  
4.5.1.  Inclusion Criteria  
Subjects must fulfill all of the following inclusion criteria to be eligible for participation in the 
study:  
1. For adu lt subjects : Participants legally competent to sign and give informed consent.  For 
pediat ric and adolescent subjects: Informed consent of parent(s) or legal guardian, and, if 
age appropriate, assent by [CONTACT_748], as required by [CONTACT_1207].  
2. Males and females , ages 6 years and older  at time of signing Informed Consent 
(Screening) . 
3. Diagnosed with mild to moderate atopic dermatitis according to the criteria of Hanifin 
and Rajka (1980) prior to or at the screening visit.  Subjects must have at least 3 of t he 
4 basic features per Hanifin and Rajka (1. Pruritus; 2. Typi[INVESTIGATOR_125044] [flexural lichenification in adults and facial and extensor eruptions in infants 
and children]; 3.  Chronic or chronically relapsing dermatitis; or 4. Personal or  family 
history of atopy), in addition to [ADDRESS_140564] 3  months in subjects 6 -17 years of age or 6 months in subjects 
>[ADDRESS_140565]’s 
medical c hart, from the subject’s physician, or through  subject /parent/caregiver  
interview. Stable disease for the past 4 weeks with no significant flares in atopic 
dermatitis before screening.  
5. EASI Score >5.  EASI is evaluated for the entire body except the scalp,  palms, and soles.  
6. vIGA -AD score of ‘Mild’ (‘2’) of ‘Moderate’ (‘3’) at Baseline /Day 1 . The vIGA -AD is 
evaluated for the entire body except the scalp, palms, and soles.  
Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 35 of 95 7. Has AD involvement of >3% BSA (excluding the scalp, palms, soles).  
8. Females of childbearing potential (FOCBP) must have a negative serum pregnancy test at 
Screening (Visit 1) and a negative urine pregnancy test at Baseline /Day [ADDRESS_140566] 12  months (post -menopausal status 
should be confirmed with FSH tes ting) or have undergone surgical sterilization 
(permanent sterilization methods include hysterectomy, bilateral oophorectomy, 
hysteroscopic sterilization, bilateral tubal ligation or bilateral salpi[INVESTIGATOR_1656]).  
10. In good health  as judged by [CONTACT_737], based on medical history, physical 
examination, vital signs, serum chemistry labs, hematology values, and urinalysis.  
11. Subjects and parent(s)/legal guardian(s) are considered reliable and capable of adhering 
to the Protocol a nd visit schedule, according to the judgment of the Investigator.  
4.5.2.  Exclusion  Criteria  
Subjects who meet any of the following exclusion criteria will be excluded from participation in 
this study:  
1. Subjects with any serious medical condition or clinically sign ificant laboratory, vital 
signs, or physical examination abnormality that would prevent study participation or 
place the subject at significant risk, as judged by [CONTACT_737]  
2. Liver function tests excursions that exceed:  
• AST or ALT > 2X ULN  
• Total biliru bin: 
− > 1.[ADDRESS_140567] or  
− > ULN and ≤ 1.[ADDRESS_140568] bilirubin is >  35% of total bilirubin  
• ALP ≥ 2x ULN  
3. Subjects who cannot discontinue medications and t reatment s prior to the Baseline visit 
and during the study according to Excluded Medications and Treatm ents (Table ). 
4. Has unstable AD or any consistent requirement for high potency topi[INVESTIGATOR_125045].  
5. Subjects who have signific ant active systemic or localized infection  (e.g., molluscum 
contagiosum) , including known actively infected AD, or have had any infection that 
required oral or intravenous administration of antibiotics, antifungal or antiviral agents 
within 14 days prior t o Baseline /Day 1 . 
Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 36 of 95 6. Subjects who are unwilling to refrain from prolonged sun exposure and from using a 
tanning bed or other artificial light emitting devices (LEDs) for 4 weeks prior to 
Baseline/ Day [ADDRESS_140569] of the study medication on AD, as determined by [CONTACT_737].  Subjects with 
any condition  on the treatment area which, in the opi[INVESTIGATOR_689], could 
confo und efficacy measurement s, e.g., molluscum contagiosum . 
8. Subjects with known genetic dermatological conditions that overlap with AD, such as 
Netherton syndrome . 
9. Known allergies to excipi[INVESTIGATOR_78413] -151 cream  
 
  
10. Subjects who cannot discontinue the use of strong cytochrome  P-450 CYP3A4  inhibitors 
e.g., indinavir, nelfinavir, ritonavir, clarithromycin, itraconazole, ketoconazole, 
nefazodone, saquinavir, suboxone and telithromycin for 2 weeks prior to the 
Baseline /Day 1  and during the study period.   
11. Subjects who cannot discontinue the use of strong cytochrome P-450 CYP3A4  inducers 
e.g., efavirenz, nevirapi[INVESTIGATOR_050], glucocorticoids, barbiturates (including phenobarbital), 
phenytoin, rifampin , and carbamazepi[INVESTIGATOR_114926] 2 weeks prior to the Baseline /Day [ADDRESS_140570] (Daxas ®, Daliresp®) within the past 
4 weeks . 
13. Known or suspected:  
• Severe renal insufficiency  
− Severe renal insufficiency is defined as calculated creatinine clearance <30 
mL/min.    
• Moderate to severe hepatic disorders (Child -Pugh B or C)  
14. History of severe depression, suicidal ideation  or behavior , Baseline/Screening C -SSRS  
(for adolescents and adults 12 years old and older)  indicative of suicidal ideation  or 
behavior , whether lifetime or recent/current  
15. Subjects with  a PHQ -8 (adults) or  modified PHQ -A (adole scents , 12-17 years old 
inclusive ) score  ≥10 at Screening or Baseline visits  
16. Subjects (6 to 11 years old, inclusive) with a CDI -2 (parent report) raw score ≥17 for 
females and ≥18 for males  at Screening  or Baseline /Day [ADDRESS_140571] -feeding . 
18. Previous treatment with ARQ -151. 

Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 37 of 95 19. Subjects currently undergoing allergy testing (e.g., food allergy testing or skin prick 
testing), patch testing, food challenges, or allergy desensitization,  or plan to do so during 
the study.  
20. Subjects with any serious medical condition  (e.g., hypo - or hyper -thyroidism)  or 
clinically significant laboratory abnormality that would prevent study participation or 
place the subjec t at significant risk, as determine d by [CONTACT_941] I nvestigator . 
21. Subjects with a history of a major surgery within 4 weeks prior to Baseline /Day [ADDRESS_140572] a major surgery planned during the study.  
22. Subjects with a history of chronic alcohol or drug abuse within 6  months prior to 
Screening . 
23. Current or a history of cancer within 5 years with the exception of fully treated  skin basal 
cell carcinoma, cutaneous squamous cell carcinoma or carcinoma in situ of the cervix.   
24. Parent(s)/legal guardian(s) who are unable to communicate, read, or understand the local 
language.  Subjects who are unable to communicate, read or understand the local 
language (s), or who display another condition, which in the Investigator’s opi[INVESTIGATOR_1649], makes 
them unsuitable for clinical study p articipation.  
25. Subjects who  are family members of the clinical study site, clinical study staff, or 
sponsor, or family members of enrolled subjects  living in the same house.  
4.6. Randomization  
Randomization will take place at the Baseline visit after the Investigator confirms that the su bject 
meets all eligibility criteria listed in Section  4.5. 
Subjects will be randomly assigned to apply ARQ -151 cream  0.15 % QD, or matching vehicle 
QD.  Assignment of drug or vehicle  will be made at a 2:1 ratio (drug:vehicle)  and stratified by 
[CONTACT_26469] -AD sco re (‘Mild’ vs. ‘Moderate’), and by [CONTACT_125071] a computer -generated 
randomization list.  Kits containing tubes  of study medication will be assigned to each subject 
using an internet -based response system (IWRS).  A subject may receive more than one kit for 
the treatment period.  The kits and tubes  are blinded and each kit is numbered with a unique kit 
number.  
4.7. Stud y Restrictions  
4.7.1.  Prohibitions and Concomitant Therapy  
Prohibited medications and products are detailed in Table  (Excluded Medications and 
Treatments) .   
Generally, the addition of new medications, including nonprescription medications, during the 
course of the study is discouraged.  However, the short -term use of a medication may be 
authorized by [CONTACT_737].  The Investigator must make the decision to  authorize the use of 
any such a medication only after consideration of the clinical situation, the potential for masking 
symptoms of a more significant underlying event, and whether the use of the medication will 
compromise the outcome or validity of the clinical investigation. Other medications may be 
authorized by [CONTACT_125072]. If medication is required, the name, 
Protocol ARQ -151-[ADDRESS_140573] been used chronically by [CONTACT_1766], in particular 
statins and anti -hypertensives, are allowed for use during the study, except as prohibited in  Table 
. No rescue medication for AD is allowed during this study up to Week 4.  
Table 2. Excluded  Medications and Treatments  
Excluded Medications and Treatments  Washout Period Prior to Day 1  
Approved b iologics such as  dupi[INVESTIGATOR_12458]  6 months  
Investigational biologics  6 months  
• Systemic treatments that could affect AD; 
e.g. corticosteroids, retinoids, calcineurin inhibitors, 
hydroxycarbamide (hydroxyurea),  methotrexate, 
cyclosporine, azathioprine, hydroxychloroquine, 
mycophenolate mofetil, or other immunosuppressive 
therapi[INVESTIGATOR_014], or systemic treatment with nonsedating 
antihistamines in a nonstable regimen.   
• Systemic treatments with nonsedating antihistamines  
(e.g., cetirizine, desloratadine, loratadine)  in a stable 
regimen is allowed.  4 weeks or 5 half -lives, whichever is 
longer  
PUVA or NBUVB phototherapy  4 weeks  
Topi[INVESTIGATOR_57961]  1 week  
Sedating antihistamines  and other over the counter remedies 
containing sedating antihistamine, such as sleep aids (e.g., 
ZzzQuil™ LIQUICAPS®SLEEP -AID), and cough/cold 
remedies (e.g., Theraflu® night time, NyQuil™ Cold & Flu 
Night time)  1 week  
Topi[INVESTIGATOR_11930], calcineurin  inhibitors, or Eucrisa®.  
Topi[INVESTIGATOR_22781], including 
soaps, dilute bleach baths, or sodium hypochlorite -based 
products anywhere on the body.  2 weeks  
Strong cytochrome P -450 CYP3A4 inhibitors e.g.,  indinavir, 
nelfinavir, ritonavir, clarithromycin, itraconazole, 
ketoconazole, nefazodone, saquinavir, suboxone and 
telithromycin  2 weeks  
Strong cytochrome P -450 CYP3A4 inducers e.g., efavirenz, 
nevirapi[INVESTIGATOR_050], glucocorticoids, barbiturates (including 
phenobarbital), phe nytoin, rifampin, and carbamazepi[INVESTIGATOR_050]  [ADDRESS_140574] (Daxas®, Daliresp®)  4 weeks  
All other investigational drugs  4 weeks or 5 half -lives, whichever is 
longer  
Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 39 of 95 Footnotes from table above:  
• Eye / ear drop and nasal corticosteroid preparations are allowed.  Inhaled corticosteroid preparations are 
allowed if used for a stable condition and at a stable dose for > 28 days before screening and are continued 
at the same dose throughout the study.  
• All subjects should apply medication each evening, except on clinic visit days  when the study product will 
be applied at the clinical site. If the subject takes an evening shower/bath, the ARQ -[ADDRESS_140575] 4 hours after study 
drug application.  Non-medicated emollients or moisturizers will be allowed once daily in a stable regimen 
as normally used by [CONTACT_748]. For subjects that apply a non -medicated emollient or moisturizer after an 
evening shower/bath, the study drug must be applied first to  the treatment areas. The non -medicated 
emollient or moisturizer can then be applied but only to other untreated areas of the subject’s skin.  
• Sunscreens will be allowed daily , as needed  by [CONTACT_125073] 2 hours after application 
of ra ndomized study drug.   
• Concomitant other medications for chronic conditions (e.g., NSAIDs, statins, anti -hypertensives) are 
permitted unless specifically prohibited in the Protocol.  
• Topi[INVESTIGATOR_8163], topi[INVESTIGATOR_12669], or any other topi[INVESTIGATOR_125046].  
4.8. Treatment  
4.8.1.  Drug Supplies, Packaging and Labeling  
ARQ -[ADDRESS_140576] will be based on the BSA involvement of atopic dermatitis .  The kits and 
tubes  will be labeled in a blinded manner.  The kit(s) dispensed to a subject will be labeled with a 
unique num ber. 
The Sponsor will supply sufficient quantities of the study drug and matching vehicle to each site 
to allow for completion of this study.  
Records will be made of the receipt and dispensing of the study drugs supplied.  At the 
conclusion of the study , any used/ unused study drugs will be returned to the Sponsor or 
designee, or destroyed, as per Sponsor instructions.  
Refer to the most current version of the IP Handling Plan for details on accountability, storage, 
and management of ARQ -151.  
4.8.2.  Blinding  
This i s a double -blind study, therefore neither the subjects nor the Investigator and clinical 
personnel will be aware of which treatment an individual subject receives.  
4.8.3.  Breaking Treatment Codes  
In the event of a medical emergency where breaking the blind is req uired to provide medical care 
to the subject, the Investigator may obtain treatment assignment directly from the IWRS system 
for that subject. Refer to the current version of the ARQ -151-[ADDRESS_140577]’s treatment assignment is disclosed to the Investigator, the subject will have the study 
treatment discontinued. All subjects will be followed until study completion unless consent to do 
so is specifically withdrawn by [CONTACT_423].  
4.8.4.  Treatment  Admini stration  
Initial treatment with the IP will occur on Day 1. ARQ -151 cream 0.15% is administered  once 
daily  as a topi[INVESTIGATOR_125047] 
2 mg/cm2.   
At Baseline visit, the study staff will demonstrate to the subject/caregiver(s) how to apply 
ARQ -[ADDRESS_140578].  Study site staff 
will be trained to ensure a unit dose (a pea size unit of ARQ -151 cream will cover approximately 
1% BSA)  is properly squeezed from the tube and applied to atopic dermatitis lesion(s) as a thin 
film and rubbed in using the index and middle finger, rubbing in thoroughly but gently, until the 
‘white’ has disappeared.  The subject/caregiver will then practice sq ueezing a similar amount 
onto their index and middle finger and apply a thin film to other areas to be treated.  At 
Baseline/ Day 1, the study staff will ensure that the subject/caregiver’s application technique is 
correct and that a thin layer is applied a s instructed (which represents an application rate of 
approximately 2 mg/cm2).    
Re-training will be conducted at subsequent  visits as needed (i.e., if the  returned tube(s) weighs 
substantially different than the expected weight).  
Subjects /caregivers will  be instructed to apply investigational product once daily to all treatment 
areas identified by [CONTACT_125074] a Body Diagram (see  Appendix 1). 
Note : 
• All subjects should apply medication each evening (except on clinic visit days  when 
the investigational product will be applied at the clinic ). If the subject takes an 
evening shower/bath, the ARQ -[ADDRESS_140579] 4 hours 
after study drug application.  
• Caregivers should wash their hands with soap and water after applying IP  to a child . 
• Parents/guardians/caregivers who are pregnant, or wome n of childbearing potential 
who are trying to become pregnant, or who are breastfeeding, or planning to 
breastfeed during the study should avoid accidental exposure by [CONTACT_125075]. 
• Subjects should maintain treatment of areas with study drug for the duration of the 
study regardless of whether treatable areas of AD clear prior to Week 4 visit.  
Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 41 of 95 • New lesions  that develop during the study should be treated (except scalp).  
An unsched uled visit is not required for starting treatment of new lesions.  
Each investigational product tube will be weighed prior to dispensing at the Baseline visit and at 
each subsequent visit. Investigational product tubes must be returned by [CONTACT_125076] s tudy 
visit, both empty and full, and will be weighed. If the subject’s actual use is substantially 
different than the expected use for the subject’s BSA (see IP Handling Plan), the 
subject/caregiver will be retrained on the study drug application technique . 
4.8.5.  Treatment Compliance  
Investigational product tubes will be weighed at each clinic visit.  
Subjects/caregivers will complete a daily diary recording the date and time of each dose applied, 
any missed doses, and a comment section should the subjects have a comment, e.g., record 
potential AEs.  Site personnel will review the diaries and use the information to question the 
subject regarding compliance and AEs and then record appropriate information in source 
documents and complete Case Report Forms (CRF s). If a subject misses a dose, they should be 
instructed to return to the protocol investigational product administration schedule (i.e. if subject 
forgets a dose they should wait until that evening and apply as usual).  
A subject will be considered compli ant with the dosing regimen if the subject meets both of the 
following requirements:  
• applies at least 80% of the expected applications during the study drug application period  
• does not miss more than [ADDRESS_140580] 
applied (via dispensed and returned tube weights) will be measured for reporting purposes.  
If the diary shows less than 80% of expected daily applications  (but not more than 3 consecutive 
missed doses), the subject is using too little study drug and retraining must be conducted and 
documented.  
Compliance will be documented in source and in eCRF . 
4.8.6.  Removal of Subjects from Study Treatment  
Subject treatment  with study drug in this trial may be discontinue d for any of the following 
reasons:  
1. Occurrence of any medical condition or circumstance that, in the opi[INVESTIGATOR_125048].  
2. Adverse Events as described in Section s [ADDRESS_140581]’s 
pregnancy.  
4. Subject's decision to discontinue treatment with study drug . 
5. C-SSRS (Section 5.1.10 ) indicative of suicidal ideation   
Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 42 of 95 6. PHQ -8 (Section 5.1.7 ) or modified PHQ -A (Section 5.1.8 ) score ≥[ADDRESS_140582] igator in consultation with mental health professional  
7. CDI-2 (Section 5.1.9 ) raw total  score of ≥[ADDRESS_140583]’s repeated failure to comply with protocol requirements or study related 
procedures.  
10. The subject interrupts trial study drug application for more  than 50% of scheduled doses.  
11. Termination of the study by [CONTACT_1034], FDA, or other regulatory authorities.  
4.8.7.  Removal of Subjects from the Study  
A subject may be removed from study participation for any of the following reasons:  
• Subject death.  
• Subject’s dec ision to wit hdraw from the study.  
• Subject is lost to follow -up. A subject will be considered lost to follow -up after three 
phone and three email attempts and documentation of a certified letter sent to the 
subject’s address.  
• Termination of the study by [CONTACT_1034], FDA, or other regulatory authorities  
5. STUDY PROCEDURES  
The Schedule of Visits and Assessments ( Section  1.3) summarizes the clinical procedures to be 
performed at each visit. Individual clinical procedures are described in detail below.  
5.1. Safety Assessment s 
This study assesses the safety and efficacy  of ARQ -151 cream . Safety will be determined by 
[CONTACT_125077] l examinations, local tolerability  assessments, vital signs /weight , clinical 
laboratory parameters, either PHQ -8 (adults , ≥18 years old ) or modified PHQ -A (adolescents , 
12-17 years old ) or Children’s Depresssion Inventory 2 (CDI -2, parent  report for childr en 6-11 
years old, inclusive ), C-SSRS (12 years and older) and AEs as outlined in the Schedule of Visits 
and Assessments  (Section  1.3).  
Additional evaluations/testing may be deemed necessary by [CONTACT_978] [INVESTIGATOR_1238]/or the Sponsor for 
reasons related to subject safety.  
5.1.1.  Screening  
Before a subject’s participation in the clinical study, the Investigator is responsible for obtaining 
written informed consent from the subject  or written assent from adolescent subjects and consent 
from their parent(s) or legal g uardian(s ) for children and/or adolescents after adequate 
explanation of the study design, anticipated benefits, and the potential risks .  A subject is 
Protocol ARQ -151-[ADDRESS_140584] provide informed consent/assent as per their age group at screening. During the 
study, if a subject change s age group, the subject  must provide informed consent/assent relative 
to his/her current age group. Subjects will continue with the assessments specific to their age 
group at the time of consent/assent at Screening . 
The following procedures/assessments will be performed at the Screening Visit (within 4 weeks 
after signing the informed consent):  
• Review of medical and surgical history  
• Collection of demographic data including sex, age, race, ethnicity  
• Vital signs including temperature,  heart rate, and blood pressure  
• Collection of body weight  (kg), and height  (cm)  
• Atopic dermatitis  assessments  (e.g., vIGA-AD, BSA, EAS I, SCORAD ) 
• Limited p hysical examination  of skin  (including assessment of Fitzpatrick skin type 
at Screening only) , lungs, and heart  
− Fitzpatrick skin phototype will be rated as follows:  
I:  Always burns easily; never tans (sensitive)  
II:  Always burns easil y; tans minimally (sensitive)  
III:  Burns moderately; tans gradually (light brown) (normal)  
IV:  Burns minimally; always tans well (moderate brown) (normal)  
V:  Rarely burns; tans profusely (dark brown) (insensitive)  
VI:  Never burns, deeply pi[INVESTIGATOR_49194] (ins ensitive)  
• Laboratory tests: hematology, chemistry, ur inalysis, serum pregnancy test (for female 
subjects of child bearing potential)  
• Completion of WI -NRS, CDI-2, DLQI , CDLQI , DFI, C-SSRS, POEM, and PHQ  (-8 
or -A) 
• Collection  of concomitant medications  and adverse events  
Subjects may be re -screened one time  and the subject will assigned a new Subject ID . 
5.1.2.  Contraception Requirements  
Females of childbearing potential (FOCBP) must have a negative serum pregnancy test at 
Screening and a negative u rine pregnancy test at Baseline ( Day 1 ). In addition, sexually active 
FOCBP must agree to use at least one form of an highly effective or barrier method of 
contraception throughout the trial  according to Contraception Requirements ( Error! Reference 
source not found. ). 
Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 44 of 95 Figure 1. Contraception Requirements for Female Subjects  
 
5.1.3.  Baseline (Day 1 ) 
Randomization will take place  at the Baseline  visit after the subject has been found to be fully 
eligible for participation. A subject will be considered enrolled into the study  upon the first IP 
application .    
If the Baseline visit occurs within 21 days of Screening  for subjects < 18 years old , the Screening 
results may be used. 
5.1.4.  Physical Examination  
Physical examinations will be performed according to the Schedule of Visits and Assessments 
(Section  1.3). The physical  exam will be limited to skin, lungs and heart only.  
5.1.5.  Vital Signs , Height  and Weight  
Vital signs will be performed according to the S chedule of Visits and Assessments ( Section  1.3). 
Blood pressure, heart rate, and temperature will be collected in seated position after [ADDRESS_140585]. For weight measurement, s ubjects will be instructed to void prior to weight being taken  and 
to remove any objects of significant weight (i.e. jackets, outerwear, shoes, cell phones, wallet, 
key chains, etc.). Weight should be obtained using a calibrated weight scale and the same scale , 
whenever possible,  should be used for a subject througho ut the duration of the study.  The 
subject should stand with both feet in the center of the scale with their arms at their side and hold 
still. Record the weight to the nearest decimal fraction (for example, 55.5 pounds or 25.1 
kilograms) . For subjects <18  years of age, measure the weight in triplicate  and report the average 

Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 46 of 95 5.1.7.  Patient Health Questionnaire depression scale (PHQ -8) 
The PHQ -8 Assessment (Appendix  2) will be performed in adult subjects according to the 
Schedule of Visits and Assessments ( Section  1.3). 
PHQ -8 score is the sum of the responses for the 8 questions.  
Five severity categories of depression are defined as follows:  
• None – Minimal depression (0 to 4)  
• Mild depression (5 to 9)  
• Mod erate depression (10 to 14)  
• Moderately severe depression (15 to 19)  
• Severe depression (20 to 24)  
A subject with a PHQ -[ADDRESS_140586] with a PHQ -8 score ≥15 should be immediate ly referr ed to a mental health 
professional , and Investigators in consultation with the mental health professional  should 
consider interruption or discontinuation of the study drug . 
5.1.8.  Patient Health Questionnaire Depression Scale (Modified PHQ -A) 
The Modified PHQ -A Assessment (Appendix  3) will be performed in adolescent subjects (12 -17 
years old , inclusive ). 
Modified PHQ -A score is the sum of the responses for for five severity categories of depression 
defined as follows:  
• None – Minimal depression (0 to 4)  
• Mild depression (5 to 9)  
• Moderate depression (10 to 14)  
• Moderately severe depression (15 to 19)  
• Severe depression (20 to 24)  
A subject  with a modified PHQ -A score of [ADDRESS_140587] with a modified PHQ -A score ≥15 should be immediate ly referr ed to a mental health 
professional , and Investigato rs in consultation with the mental health professional  should 
consider interruption or discontinuation of the study drug .  
Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 47 of 95 5.1.9.  Children’s Depression Inventory  2 
The CDI -2 Assessment  will be performed according to the Schedule of Visits and Assessments  
(Section  1.3) for subjects 6 to 11 years old, inclusive . 
The CDI -2 quantifies depressive symptomatology using reports from children/adolescents, 
teache rs, and parents or caregivers. It is recommended for use in initial evaluation and is 
appropriate when there is a need for an assessment and robust description of a child’s depressive 
symptoms.  
This study will use the CDI Parent Report Form. An example of the Parent report form is 
presented in Appendix 4. 
A subject  with a CDI -2 raw score of ≥21 for females and ≥[ADDRESS_140588] with a CDI-2 raw total  score of ≥32 should be r eferr ed to a mental health professional , 
and Investigators  in consultation with the mental health professional should consider interruption 
or discontinuation of the study drug . 
5.1.10.  Columbia -Suicide  Severity  Rating  Scale  (C-SSRS)  
C-SSRS Assessments will be performed according to the Schedule of Visits and Assessments  
(Section  1.3) for subjects 12 -years old  and older . 
The administration schedule of the C -SSRS will be : 
• The “Baseline /Screening ” version  (Appendix  4) will be used at Screening to provide 
a pre -treatment assessment.  
• On all subsequent visits, the “Since Last Visit ” version  (Appendix  6) will be used  
(Baseline /Day 1 , Week 1 /Day 8 , Week 2 /Day 15  or Week 4 /Day 29 ). 
• A score greater than [ADDRESS_140589] in the study . 
• Any score greater than [ADDRESS_140590] 
to discontin ue from the study drug  and prompt referral to a n identified  mental health 
professional and/or an appropriate  emergency room. The Medical Monitor should be 
contact[INVESTIGATOR_530].    
The C -SSRS administ er will be trained via the C -SSRS training video . A training certificate  for 
the administer(s) will be on file in the trial master file at the site . 
The Investigator must review the completed C -SSRS.  A qualified mental health care provider 
must be available, immediately if needed, to refer the subject for further evaluation.  
5.1.11.  Local Tolerability Assessment  
The Investigator  Local Tolerability Assessment will be performed according to the Schedule of 
Visits and Assessments  (Section  1.3).  
Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 48 of 95 Application site reactions will be graded at each timepoint. Irritation reactions are graded using 
the scale detailed in the following  section  (Berger, 1982 ). Reactions at the site of product 
application, which may occur post -Baseline, should be differentiated from the preexisting 
inflammation associated with the subject’s atopic der matitis . 
The investigator assessments will be conduc ted by [CONTACT_125078] a properly trained and 
designated subinvestigator  prior to study drug application in the clinic.  
Dermal Response  
0. no evidence of irritation  
1. minimal erythema, barely perceptible  
2. definite erythema, readily visible; minimal edema or minimal papular response  
3. erythema  and papules  
4. definite edema  
5. erythema, edema and papules  
6. vesicular eruption  
7. strong reaction spreading beyond application site  
Other Effects  
A. = slight glazed appearance  
B. = marked glazing  
C. = glazing with peeling and cracking  
D. = glazing with fissures  
E. = film of dried serous exudates  
F. = small petechial erosions and/or scabs  
G. = no other effects  
 
The Subject  Local Tolerability Assessment will be performed according to the Schedule of Visits 
and Assessments  (Section  1.3). 
The subject will assess burning/stinging (0 -3 score) :  
Grade  Sensation Following Drug Application  
0 (none)  No sensation  
1 (mild)  Slight warm, tingling sensation; not really bothersome  
2 (moderate)  Definite warm, tingling sensation that is somewhat bothersome  
3 (severe)  Hot, tingling/stinging sensation that has caused definite discomfort  
 
This assessment will be administered by [CONTACT_779] 10 to 15 minutes after study drug application in 
the clinic at Baseline and at every clinic visit.  
• Note : for subject burning stinging assessment  at Day 29, subjects will provide a 
recall assessment of burning/stinging experienced p ost drug application on the 
previous day (Day 28).  
Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 49 of 95 5.1.12.  Adverse Events  
Adverse events  (AEs) will be collected and assessed throughout the study according to the 
Schedule of Visits and Assessments  (Section Error! Reference source not found. ).The 
Investigator is responsible for ensuring that all adverse events observed by [CONTACT_125079]’s medical record and the eCRF.  
The Investigator is responsible for ensuring that all serious adverse events observed by [CONTACT_125080] r after signing of the informed consent through 
[ADDRESS_140591] or the end of study 
(whichever is later) are recorded in the subject’s medical record and are submitted per SAE 
reporting requireme nts (Section 5. 7.5). 
AEs (whether serious or non -serious) and clinically significant abnormal laboratory test value(s) 
will be evaluated by [CONTACT_978] [INVESTIGATOR_78430]/or followed up for up to 30 days after end of 
treatment or until the symptoms or value(s) ret urn to normal, or acceptable levels, as judged by 
[CONTACT_978].  Refer Section  5.[ADDRESS_140592]  >3% BSA of AD involment (excluding the scalp, 
palms, soles). Palms and soles may be treated with investigational product in this study, but will 
not be counted towards vIGA-AD, EASI, or BSA assessments. EASI  is evalua ted for the entire 
body except the scalp, palms, and soles. . 
5.2.1.  Validated Investigato r Global Assessment Scale for Atopic Dermatitis  
Validated Investigator Global Assessment scale for Atopic Dermatitis (vIGA -AD) 
assessments should be completed prior to  other physician assessments.  
vIGA -AD assessment will be performed according to the Schedule of Visits and Assessments  
(Section  1.3). The vIGA -AD is a static evaluation of qualitative overall AD severity. This global 
assessment scale is an ordinal scale with five severity grades (reported only in integers of 0 to 4). 
Each grade is defined by a distinct and clinically relevant morphologic description that 
minimizes inter -observer variability (see Error! Reference source not found. ). vIGA -AD is 
evaluated for the entire body except the scalp, palms, and soles.  
Note : All atopic dermatitis lesions on a subject will be treated including the face, trunk, 
genitals/skin folds, or limbs (excluding the scalp). The palms and soles will be treated but will 
not be counted towards any measurements of efficacy (EASI, vIGA -AD, BSA).  
Every effort must  be made for the same Evaluator to complete the IGA for the subject at 
every study visit.  
IGA will be assessed at clinic visits prior to the subject applying Investig ational Product at 
the site .  
5.2.2.  Eczema  Area and Severity Index (EASI)  
EASI scores (Hanifin, 2001 ) will be performed according to the Schedule of Visits and 
Assessments  (Section  1.3) 
Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 50 of 95 Four anatomic sites —head, upper extremities, trunk , and lower extremities —are assessed for 
erythema, induration /infiltration  (papules), excoriati on, and lichenification as seen on the day of 
the examination. The severity of each sign is assessed using a 4 -point scale  (half steps are 
allowed; e.g. 0.5, 1.5 and 2.5 ): 
• 0 = none  
• 1 = mild 
• 2 = moderate  
• 3 = severe  
The area affected by [CONTACT_125081] a given anatomic site is estimated as a percentage 
of the total area of that anatomic site and assigned a numerical value according to the degree of 
atopic dermatitis involvement as follows:  
• 0 = no involvement  
• 1 = 1-9% 
• 2 = 10-29% 
• 3 = 30-49% 
• 4 = 50-69% 
• 5 = 70-89% 
• 6 = 90-100% 
The EASI score is obtained by [CONTACT_125082] ≥8 years old : 
EASI = 0.1 ( Eh + I h + Exh + L h) A h + 0.2 ( Eu + Iu + Exu + Lu) A u + 
0.3 (Et + I t + Ext + Lt) A t + 0.4 ( El + I l + Exl + Ll) Al 
The EASI score is obtained by [CONTACT_125083] <8 years old : 
EASI = 0.2 ( Eh + I h + Exh + L h) A h + 0.2 ( Eu + Iu + Exu + L u) A u +  
0.3 (Et + I t + Ext + L t) A t + 0.3 ( El + I l + Exl + L l) Al 
Where E, I, E x, L, and A denote erythema, induration, excoriation, lichenification and area, 
respectively, and h, u, t, and l denote head, upper extremities, trunk, and lower extremities, 
respectively.  
Note : Palms and soles may be treated with investigational product in thi s study, but will not be  
counted towards IGA, EASI, or BSA assessments. EASI  is evaluated for the entire body except 
the scalp, palms, and soles.  
5.2.3.  Worst  Itch Numerical Rating Scale (WI -NRS)  
 
The WI -NRS has been developed as a simple, single item to assess the patient -reported severity 
of this symptom at its highest intensity during the previous 24 -hour period. (Newton, et al., 
2019).  The WI-NRS will be determined by [CONTACT_423]’s recording of daily assessment of worst 
itch over the past 24  hours. The scale is from ‘0 to 10’ (“no itch” to “worst itch imaginable ” or 
“worst imaginable  itch”).  
Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 51 of 95 WI-NRS Assessments will be performed according to the Schedule of Visits and Assessments 
(Section  1.3) starting 7 days prior to the Baseline/Day 1 clinic visit  (during the 7 days prior to 
Baseline/Day [ADDRESS_140593] the WI -NRS value every day) . 
5.2.4.  Dermatology Life Quality Index (DLQI) and Children’s Dermatology Life 
Quality Index (CDLQI)  
The DLQI (ages 17+ years) and CDLQI (ages 6-16 years , inclusive ) will be performed according 
to the Schedule of Visits and Assessments ( Section  1.3). The DLQI/CDLQI is a simple, self -
administered and user -friendly validated questionnaire. The DLQI/CDLQI is designed to 
measure the health -related quality of life of  adult patients suffering from a skin disease. The 
DLQI/CDLQI consists of 10 questions concerning patients' perception of the impact of skin 
diseases on different aspects of their health -related quality of life over the last week. 
Subjects/caregivers will complete the CDLQI/DLQI. Refer to Error! Ref erence source not 
found.  for the DLQI  and Appendix [ADDRESS_140594] Questionnaire (DFI)  
This questionnaire measures how much having a child with atopic dermatitis affects the quality 
of life of other (adult) members of the family.  To be completed by  [CONTACT_3654]/guardians/ caregivers 
of subjects ≤17 years of age  (Appendix 10).   
5.3. Other  Evaluations  
5.3.1.  Body Surface  Area (BSA)   
BSA assessments will be performed according to the Schedule of Visits and Assessments 
(Section  1.3). 
The BSA affected for atopic dermitis  will be determined by [CONTACT_423]’s hand method,  where the 
subject’s hand (including fin gers) surface area is assumed to equal 1% of bod y surface area 
(excluding the scalp,  palms, soles ).  
5.3.2.  SCORAD  ("SCORing Atopic Dermatitis")  
SCORAD is a clinical tool for assessing the severity (i.e. extent, intensity) of atopic dermati tis as 
objectively as possible. It gives approximate weights of 60% to intensity and 20% each to spread 
(extent) and subjective signs (insomnia, etc.).  
See Appendix 11. 
5.3.3.  Patient -Oriented Eczema Measure  (POEM)  
 
The Patient -Oriented Eczema Measure (POEM) is a tool used for monitoring atopic eczema 
severity. It focuses on the illness as experienced by [CONTACT_102].   
POEM is a 5 -point scale measuring the frequency of each of seven AD symptoms (dryness, 
itching, flaking, cracking, sleep loss, bleeding, and weepi[INVESTIGATOR_007]) over the past week scored as 
occurring “no days” (0), “1 to 2 days” (1), “3 to 4 days” (2), “5 to 6 days” (3) or “every day” (4). 
Total score ranges from 0 –28, with higher score indicating greater symptom impact .See 
Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 52 of 95 Appendix  12. The self/proxy  report questionnaire will be used in this study  (for children unable 
to read and/or understand the POEM questionnaire, the parent/guardian/caregiver will complete 
the questionnaire) . 
5.3.4.  Pharmacokinetic s Assessment  
 
PK draws will be performed according to the Schedule of Visits and Assessments ( Section  1.3) 
for all subjects at all sites : 
 
• A single PK assessment (trough) wil l be performed in all subjects with a blood 
sample collected at Week 4/Day 29 . 
Ensure study medication  is not applied in the area where PK will be drawn.  
5.3.5.  Medical Photography   
Photography of AD lesion(s) selected by [CONTACT_125084], except Week 2 /Day 15 .  All efforts will be made to de -identify the 
subjects. Canfield equipment will be used to capture photographs . 
Photography should be focused on single lesions or specific body sections (e.g. arm). Body or 
half body photos should only be taken if necessary. Subjects who are unwilling to participate in 
the medical photography will be allowed to opt out of this proced ure and documented on the 
informed consent.  
Refer to the current Photography Manual for instructions regarding photography.  
5.4. Final Study Visit – End of Study  
The approximate final study visit will occur at Week 4/Day 29. The procedures performed 
during this visit  are as described in the Schedule of Visits and Assessments  (Section  1.3). A 
3-day scheduling window  is allowed for this visit. Adverse events will be recorded as reported 
by [CONTACT_125085]  (as necessary).  
5.5. Early Termination Visit  
If a subject is withdrawn or wishes to exit the study, a termination visit will be scheduled. This 
visit should include the procedures and assessments that would be performed at the Week 4/Day 
29 visit. 
5.6. Unscheduled Visit  
Unscheduled visits may be necessary  to repeat testing following abnormal laboratory results, for 
follow -up of AEs, or for any other reason, as warranted in the judgement of the Investigator.  
The following information will be collected for all subjects:  
• Concomitant medications/procedures  
• AEs 
The following information also will be collected:  
Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 53 of 95 • vIGA -AD and EASI  
• BSA affected with AD  
• Local tolerability assessment (by [CONTACT_10670])  
The rules for how to tally vIGA-AD, BSA or other proportions of categorical responses will be 
described in the Statist ical Analysis Plan.  
5.7. Adverse Event s 
5.7.1.  Adverse Event  Definition  
An AE  is defined as any untoward medical occurrence associated with the use of a drug in 
humans, whether or not considered drug related. An AE can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding), symptom, or disease temporally 
associated with the use of a medicinal (investigational) product, whether or not related to the 
medicinal (investigational) product.   
A treatment emergent adverse event (TEAE) is de fined as an AE that started post application of 
study medication at the Baseline visit  or was present at treatment initiation but worsened during 
treatment,  through study completion.  
The definition of AEs includes worsening of a pre -existing medical condition.  Worsening 
indicates that the pre -existing medical condition has increased in severity, frequency, and/or 
duration or has an association with a worse outcome.  When recording such events, provide 
descriptions that the pre -existing condit ion has changed (eg,worsening hypertension for a subject 
with pre -existing hypertensi on).  A pre -existing condition that has not worsened during the study 
or involves an intervention, such as elective cosmetic surgery or a medical procedure while on 
study,  is not considered an AE.  
Progression of treatment indication including new or worsening of anticipated clinical signs 
or symptoms, which are collected as clinical efficacy variables and assessed as unequivocally 
associated with the disease progression and  /or lack of efficacy, should NOT be reported as 
adverse events unless the disease progression is greater than anticipated in the natural course 
of the disease.  
In general, abnormal laboratory findings without clinical s ignificance (based on the 
investigat or’s judgment) are not to be recorded as AEs.  However, abnormal laboratory findings 
that result in new or worsening clinical sequelae, or that require therapy or adjustment in current 
therapy, are considered AEs.  Where applicable, clinical sequelae (not the laboratory 
abnormality) are to be recorded as the AE.  
5.7.2.  Serious Adverse Event  Definition  
The definitions and reporting requirements of the Food and Drug Administration (FDA)/ ICH 
Guidelines for Clinical Safety  Data Management, Definitions and Standards fo r Expedited 
Reporting, Topic E2A will be adhered to.  Statements regarding mandatory reporting of all 
serious unexpected adverse drug reactions (S[LOCATION_003]Rs) to Health Canada [as per C.05.014 (1) of 
the FDR] will be ad hered. If any AEs are serious, as defined by [CONTACT_125086], required  procedures will be followed.   
Protocol ARQ -151-[ADDRESS_140595] 1 of the 
following serious criteria:  
• Fatal  
• Life-threatening  (places the subject at immediate risk of death)  
• Requires inpatient hospi[INVESTIGATOR_1081]  
• Results in a persistent or significant incapacity /disability   
• Congenital anomaly/birth defect .   
• Other i mportant medical events that, based upon appropriate medical judgment, may 
jeopardize the subject and may require medical or surgical intervention to prevent one 
of the outcomes listed in the  above definition.  
Hospi[INVESTIGATOR_4592]:  
• Rehabilitation facilities, hospi[INVESTIGATOR_78428] (e.g. caregiver relief)  
• Nursing homes or skilled nursing facilities  
• Emergency room visits  
• Same day surgeries (as outpatient/sa me day/ambulatory procedures)  
• <24 hour admissions for observation or evaluation  
Hospi[INVESTIGATOR_4595] a precipi[INVESTIGATOR_2505], clinical AE is 
not in itself an SAE.  Examples include:  
• Admission for treatment of a preex isting condition that did not worsen  
• Hospi[INVESTIGATOR_78429], social, and/or convenience admissions  
• Pre-planned treatments or surgical procedures should be noted in the baseline 
documentation for the individual subject.  
• Diagnostic an d therapeutic procedures, such as surgery, should not be reported as 
AEs; however, the medical condition for which the procedure was performed should 
be reported if it occurs during the reporting period and meets the definition of an AE.  
For example, an a cute appendicitis that begins during the AE reporting period should 
be reported as an AE, and the resulting appendectomy should be recorded as 
treatment of the AE.  
Unexpected is defined as an AE that is not listed in the IB or is not listed at the specific ity or 
severity that has been observed; or is not consistent with the risk information described in the 
general investigational plan or study document . 
If a SAE occurs to a subject on this study, contact [CONTACT_125087] .  
5.7.3.  Suspected  Unexpected  Serious Adverse Reaction (S[LOCATION_003]R)  
S[LOCATION_003]R  is defined as a serious adverse reaction, the nature or severity of which is not consistent 
with the known study treatment infor mation. A serious event or reaction is not defined as a 
Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 55 of 95 S[LOCATION_003]R when: ‘it is serious but expected’ or it does not fit the definit ion of an SAE, whether 
expected or not.  
5.7.4.  Safety Review  with Subject  
At each subsequent clinic  visit after the screening visit , subjects will be queried with an 
open -ended question such as: ‘How have you been feeling since your last visit?’  Additionally, 
the study staff will review subject  diaries and, if it appears that a potential AE was recorded, 
study staff  will query the subject and determine if an AE occurred.   
AEs (whether serious or non -serious) and clinically significant abnormal laboratory test v alue(s) 
will be evaluated by [CONTACT_978] [INVESTIGATOR_78430]/or followed for up to one month after end of 
treatment until the symptoms or value(s) return to normal, or acceptable levels, as judged by [CONTACT_3786] . 
Where appropriate, medical test(s) and/or exami nation(s) will be performed to document 
resolution of event(s). Outcome may be classified as resolved, improved, unchanged, worse, fatal 
or unknown (lost to follow -up). 
5.7.5.  Adverse Event Reporting  
The Investigator is responsible for recording all adverse event s, observed by [CONTACT_125088].  Serious adverse events observed by [CONTACT_125089].  
All adverse events that meet the criteria for “serious” (i.e., SAEs) will be reported to the Sponsor 
via fax or e -mail within 24 hours of becoming aware of the event, whether or not the serious 
events are deemed drug -related.   Reporting should be done by [CONTACT_125090] e -mail address (faxing can also be done as a second option in case e -mailing is 
not possible).  
Safety Contact [CONTACT_7171]:  
 
All serious event reporting will adhere to ICH E6: Guideline for Good Clinical Practice and ICH 
E2A: Clinical Safety Data Management: Definitions and Standards for Expedited 
Reporting.   The IRB will be notified of the Alert Reports as per FDA, ICH and the IRB’s 
policies and procedures. The sponsor, or delegate, will be responsible for report ing SAEs to 
health authorities per local reporting requirements.  The Investigator will be responsible for 
reporting events to their respective IRBs in accordance to the IRB requirements.  
The I nvestigator  will review each adverse event and assess its relationship to Investigational 
Product  (unrelated, unlikely,  possibly, probably, likely). Each sign or symptom reported will be 
graded on the NIH NCI  CTCAE toxicity grading s cale 5 -point severity scale (Grade 1, 2, 3, 4 
and 5). The date and time  of onset, time relationship to drug dosing, duration, and outcome 
(resolved, improved,  unchanged, worse, fatal, or unknown/lost to follow -up) of each event will 
be noted.  

Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 56 of 95 • The relations hip of each AE to the Investigational Product  will be assessed using the 
following definitions:  
Unrelated  • The AE must clearly be caused by [CONTACT_423]’s clinical state, or the study 
procedure/conditions.  
• Definitely not related to drug.  
• Temporal sequence of  an AE onset relative to administration of drug not 
reasonable.  
• Another obvious cause of an AE.  
Unlikely  • Time sequence is unreasonable.  
• There is another more likely cause for an AE.  
Possibly  • Corresponds to what is known about the drug.  
• Time sequence is reasonable.  
• Could have been due to another equally, likely cause.  
Probably  • Is a known effect of the drug.  
• Time sequence from taking drug is reasonable.  
• Ceases on stoppi[INVESTIGATOR_1478].  
• Cannot be reasonably explained by [CONTACT_20612]’s 
clinical state.  
Likely  • Is a known effect of the drug (e.g., listed in Physicians' Desk Reference, 
Compendium of Pharmaceuticals and Specialties, IB).  
• Time sequence from taking drug is reasonable.  
• Event stops upon stoppi[INVESTIGATOR_21395], event returns upon restarting drug.  
The following  CTCAE toxicity grading scale 5 -point severity sca le definitions for rating 
maximum severity will be used:  
Grade 1  Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated.  
Grade 2  Moderate; minimal, local or noninvasive intervention indicated; limiting age -
appropriate instrumental activities of daily living.*  
Grade 3  Severe or medically significant but not immediately life -threatening; Hospi[INVESTIGATOR_125049]; disabling; limiting self -care activities of 
daily living.**  
Note : An experience may be severe but may not be serious, e.g.,  severe headache).  
Grade 4  Life-threatening consequences;  urgent intervention indicated.  
Grade 5  Death related to AE.  
Note:  A semi -colon indicates ‘or’ within the description of the grade.  
* Instrumental activities of daily living refer to preparing meals, shoppi[INVESTIGATOR_3112], using the 
telephon e, managing money, etc.  
** Self-care activities of daily living refer to bathing, dressing and undressing, feeding self, using the toilet, taking 
medications, and not bedridden.  
AEs will be coded using the most current MedDRA® version available  at the star t of the study . 
Protocol ARQ -151-[ADDRESS_140596] they might be pregnant (e.g., missed or late menstrual period).  If 
pregnancy is confirmed, Investigat ional Product must be discontinued immediately, the subject 
should be referred to an obstetrician experienced in reproductive toxicity for evaluation and 
counseling, and the subject should be followed until conclusion of the pregnancy.  
The investigator is  responsible for reporting all available pregnancy information on the 
pregnancy report  and submitting to the Medical Monitor within [ADDRESS_140597]  experiences :  
• A serious ad verse event (SAE) or a clinically significant non -serious AE which in the 
opi[INVESTIGATOR_125050]’s well -being . 
• A treatment -emergent severe (Grade 3) laboratory abnormality (confirmed by [CONTACT_125091] ; see Appendix 13 for more infomation ). 
A subject with a PHQ -8 or modified PHQ -A score ≥15 should receive immediate referral to a 
mental health professional , and Investigators in consultation with the mental health professional  
should consider interruption or discontinuation of the study drug  
• Subjects  with a PHQ -8 or modified PHQ -A score of 10 -14 should be referred to a 
mental health professional for evaluation, regardless of the reason for their change in 
score 
Subjects with a CDI-2 raw total  score of ≥32 should be referred  to a mental health professi onal, 
and Investigators  in consultation with the mental health professional should consider interruption 
or discontinuation of the study drug  
• Subjects with a CDI -2 raw score of ≥21 for females and ≥[ADDRESS_140598]’s pregnancy.   
Treatment should be interrupted:  
• If a subject develops an application site reaction with the clinical appearance of an 
‘irritation reaction’, and with a severity of a Dermal Response Score of 5 (erythema, 
edema and papules) or greater on the scale of Berger and Bowman, treatment should 
be interrupted for up to one week and may then be resumed if the reaction has, in the 
opi[INVESTIGATOR_689], adequately resolved.   
Treat ment should be discontinued:  
• If the  application site  reaction reoccurs, treatment should be discontinued 
permanently, and the subjec t followed until the reaction resolves.   
For cases of suspected allergic contact [CONTACT_8748], the medical monitor and sponso r should be 
notified and there should be discussion about performing patch testing to further evaluate. Patch 
testing is encouraged in such cases.  
In the event of a medical emergency where unblinding is required to provide medical care to the 
subject, refe r to the most current IWRS User Manual  (Section  4.8.3 ). Contact [CONTACT_125092].  
6. DATA ANALYSIS  
Data will be handled and processed according to the Contract Research Organization’s  Standard 
Operating Procedures, which are written based on the principles of GCP.  
6.1. Statistical Methods  
The methodology presented below is a summary of the more detailed analysis plan that will be 
presented in the Statistical Analysis Plan (SAP).   The SAP will be finalized before the database 
is locked and unblinded . Any changes to the methods described in the final SAP will be 
described and justified in the clinical study report.  
All statistical processing will be performed using SAS® (Version 9. 4) unless otherwise stated.  
6.2. Determination of Sample Size  
There are ap proximately [ADDRESS_140599] the key secondary 
endpoint of IGA success in subjects with a vIGA -AD score of ‘Moderate’ at randomization, 
approximately [ADDRESS_140600] vIGA‑AD score of ‘Moderat e’ at 
randomization.  Randomization  will be stratified by [CONTACT_26469] -AD score (‘Mild’ vs. ‘Moderate’)  and 
study site.  
This sample size provides  approximately 95% power to detect an overall 15% difference 
between treatment groups on vIGA‑AD success at week 4 at α-0.05 using a 2 -sided stratified 
(vIGA -AD at randomization and age group) Cochran -Mantel -Haenszel test .  The results from a 
Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 59 of 95 recent phase 2 study (ARQ ‑151-212) of ARQ -151 cream 0.15% compared to vehicle treatment 
were used to estimate the treatment differen ce.  Specifically, in the phase 2  trial, approximately 
37% of subjects demonstrated vIGA -AD success at week 4  in the ARQ -151 0. 15% group 
compared to  22% in the vehicle group.   This sample size also provides approximately 90% 
power to detect an overall 17% difference between treatment groups on IGA success at week 4 
among subjects with vIGA -AD score ‘moderate’ at randomization.  The same testing method, 
the stratified Cochran -Mantel -Haenszel test, will be used as for the primary endpoint.  
To control for multiple comparisons, the key secondary endpoint will only be tested if the 
primary endpoint demonstrates statistical significance.  In addition, the remaining secondary 
endpoints will be inferentially tested only if the primary and key secondary endpoint 
comparisons are statistically significant.  To control for multiple comparisons among the 
remaining secondary endpoints, partitioning of alpha and the Holm’s procedure will be used.  
6.3. Subjects to Analyze  
The analysis populations are defined as follows:  
• Safet y population will include all subjects who are enrolled and received at least one 
confirmed dose of study medication.  
• Intent -to-Treat (ITT) population will include all subjects who are randomized.  
• vIGA -AD Moderate ITT population will be a subset of the IT T population with 
vIGA -AD score ‘moderate’ at randomization . 
• WI-NRS population will be a subset of the ITT population with WI -NRS score  4 at 
baseline . 
• Pharmacokinetic (P K) population will include all subjects receiving the active drug 
with quantifiable  plasma concentrations of roflumilast.   
6.4. Background and Demographic Characteristics  
Descriptive statistics will be used to summarize demographic characteristics (age, sex, ethnicity, 
and race) and background characteristics for the  randomized subjects .   
6.5. Study Medication Compliance  
The number of study drug applications by [CONTACT_125093] (mean, standard deviation [SD],  median, minimum, and maximum), and 
categorically.  
Protocol ARQ -151-[ADDRESS_140601] application compliance will be calculated based on number of 
applications divided by [CONTACT_125094] (amount) of  investigational prod uct applications 
for each subject.  Compliance will be summarized descriptively by [CONTACT_1570].  
6.6. Safety Analysis  
Descriptive statistics will be calculated for quantitative safety data and frequency counts will be 
compi[INVESTIGATOR_125051]. The safety population will be used for these 
analyses.  
Adverse Events:  
The subject incidence of treatment -emergent adverse events (TEAE) will be summarized 
overall, by [CONTACT_926], and by [CONTACT_125095].  
Clinical Laboratory Results:  
Shifts in clinical laboratory  parameters from baseline to worst post -baseline grade will be 
provide d.   
Vital Signs:  
The subject incidence of >5% weight loss or gain on study will be provided, as well as 
whether weight loss was explained or unexplained . 
6.7. Efficacy Analysis  
The Primary Efficacy Endpoint will be tested in all randomized subjects and defined  as:  
• The proportion of all randomized subjects who attain IGA Success, defined as a 
vIGA -AD score of ‘clear’ or ‘almost clear’ PLUS a [ADDRESS_140602] the key secondary endpoint defined as:  
• The proportion of randomized subjects with a vIGA -AD score of ‘Moderate’ at 
randomization who atta in IGA Success  at week 4  
Missing IGA scores will be impute d using multiple imputation.  
Upon successful demonstration of statistical significance for the secondary endpoint, the 
remaining endpoints will be grouped into secondary endpoint family 1, comprised of the 4‑point 
reduction on the WI -NRS, and secondary end point family 2, comprised of the EASI -75 at week 
4, vIGA -AD of ‘clear’ or ‘almost clear’ at week 4, time to achievement of vIGA -AD success, 
and time to achievement of EASI -75.  An alpha level of 0.[ADDRESS_140603] the endpoints in 
Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 61 of 95 secondary endpoint family 2.  The Holm procedure will be used to control for multiple 
comp arisons within secondary endpoint family 2.  The endpoints listed below will be tested 
among all randomized subjects, unless otherwise noted.   
Secondary Endpoint Family 1  (=0.03)  
• Among subjects with baseline WI -NRS  4, the proportion of subjects who attain a 4 -
point reduction in the WI -NRS at week 4  
Secondary Endpoint Family 2  ( = 0.02, Holm’s procedure)  
• The proportion of subjects who attain at least a 75% reduction in the Eczema Area 
and Severity Index at W eek 4 (EASI -75)  
• Proportion of patients with v IGA-AD score of ‘clear’ or ‘almost clear’ at week 4  
• Time to achievement of vIGA -AD success  
• Time to achievement of EASI -[ADDRESS_140604] study drug application.  All reported TE AEs will be summarized by [CONTACT_56842]. 
Descriptive statistics will be calculated for quantitative safety data and frequency counts will be 
compi[INVESTIGATOR_125052].  
Adverse Events:  
The subject incidence of treatment -emergent adverse events (TEAE) will be summarized overall, 
by [CONTACT_926], and by [CONTACT_125095].  
Clinical Laboratory Results:  
Shifts in clinical laboratory para meters from baseline to worst post -baseline grade will be 
provided.   
Vital Signs:  
The subject incidence of >5% weight loss or gain on study will be provided, as well as whether 
weight loss was explained or unexplained .   
6.9. Body Surface  Area  
Body surface are a (BSA) affected by [CONTACT_125096].  
Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 62 of 95 6.10. Local Tolerance Assessment  
For Investigator’s assessment , the numeric application site reaction scores will be summarized 
individually by [CONTACT_78463], as well as mean/median scores . 
6.11. Medical History and Physical Examinations  
Medical history for all subjects will be presented descriptively by [CONTACT_46642] .  
Physical examination for all subjects will be presented descriptively by [CONTACT_46642] .  Changes in 
physical examinations will be described in the text of the final report.  
6.12. Clinical Laborat ory Results and Vital Signs  
All clinical la boratory results and vital signs measurements and their change from baseline 
(pre-dose), will be summarized descriptively by [CONTACT_46642], visit , and treatment group  along with  
time point of collection.  
A shift table describing out -of-normal range shifts will  be provided for clinical laboratory results.  
A shift table will identify subjects who gain or lose >5% body weight over the course of the 
study.  
6.13. Prior and Concomitant Medications  
Prior and concomitant medication information for all randomized subjects wi ll be presented in a 
by-subject listing.  Summary tables will be presented by [CONTACT_78464] -Anatomical 
Therapeutic Chemical Classification System (WHO -ATC) therapeutic category and product.  
6.14. Subject Reported Outcomes Analyses  
WI- WI-NRS scale wi ll be analyzed for change from Baseline ( measured as a weekly average 
during the week before the Baseline/Day 1 visit)  in itch severity  of at least 4 at Week 4 /Day 29  
as a weekly average during the week before the Week 4 /Day 29  visit.  
6.14.1.  Dermatology Life Quality Index es, Children’s Dermatology Life Quality Index , 
SCORAD and POEM   
Dermatology Life Quality Index (DLQI), Children’s Dermatology Life Quality Index (CDLQI), 
the Dermatitis Family Impact (DFI), the Scoring Atopic Dermatitis (SCORA D), and the Patient -
oriented Eczema Measure (POEM)  will be analyzed by [CONTACT_125097] 4.  These efficacy endpoints will be analyzed descriptively.  
6.15. Pharmacokinetic Analysis  
Plasma drug concentrations will be summarized us ing using descriptive statistics, reporting n, 
mean, standard deviation, median, minimum, and maximum.  The PK population will be used for 
these analyses.  
Protocol ARQ -151-[ADDRESS_140605]  
Before screening of subjects  into the study, the curr ent protocol , ICF, and any accompanying 
material to be provided to the subjects  will be reviewed and approved by [CONTACT_4215] , as 
required by [CONTACT_8415]  (21 CFR  § 56) and ICH GCP  regulations.   A letter documenting the  IRB 
approval must be received by [CONTACT_78466] a  clinical site. 
Amendments to the protocol will be subject to the same requirements as the original protocol.   
The Investigator, Sponsor, or designee will submit a progress re port at lea st once yearly to the 
IRB. However, the frequency of these r eports will depend on IRB  requirements. As soon as 
possible after completion or termination of the study, the Investigator will submit a final report to 
the IRB per the IRB  requirements , and in compliance with FDA  and ICH GCP guidelines . 
The Investigator, the Sponsor, or designee shal l promptly notify the IRB  of any SAEs, S[LOCATION_003]Rs, 
or any other information that may affect the safe use of the study drug(s) duri ng the study, per 
the IRB  local requirements, and in compliance with FDA  regulations  and ICH GCP guidelines . 
7.1.2.  Ethical Conduct of the Study  
This research will be carried out in accordance with the protocol,  the principles of the 
Tri-Council Policy Statement (TCPS), t he ethical principles set forth in the Declaration of 
Helsinki, and the ICH harmonized tripartite guideline regarding GCP  (E6 Consolidated 
Guidance, April  1996).  
7.1.3.  Subject Information and Consent /Assent  
The investigator is responsible for obtaining written informed consent from each individual 
participating in this study after adequate explanation (in non -technical terms) of the aims, 
methods, objectives, and potential hazards of the study and before unde rtaking any study -related 
procedures . The investigator must use the most current IRB- or IEC-approved consent form for 
documenting written informed consent. Subjects will be assured that they may withdraw from 
the study at any time without jeopardizing the ir medical care. Each informed consent (or assent 
as applicable) will be read, appropriately signed and dated by [CONTACT_29159]’s legally 
authorized representative and the person conducting the consent discussion, and also by [CONTACT_125098].  
Subjects will be given a signed copy of their ICF /assent . 
7.2. Study Completion and Termination  
7.2.1.  Study Completion  
The study is considered completed with the last visit of the last subject participating in the st udy. 
The final data from the investigational site will be sent to the Sponsor (or designee) after 
completion of the final subject visit at that site, in the time frame specified in the Clinical Trial 
Agreement.  
Protocol ARQ -151-[ADDRESS_140606] been collected and a site closure visit has been performed. The investigator 
may initiate site closure at any time, provided there is reasonable cause and sufficient notice is 
given in advance of the intended termination.   
Reaso ns for the early closure of an investigational site by [CONTACT_79981]:  
• Failure of the investigator to comply with the protocol, the Sponsor’s procedures, or 
GCP guidelines.  
• Inadequate recruitment of subjects by [CONTACT_093].  
• Discontinuation of further drug development.  
7.3. Study Monitoring  
Prior to the initiation of the clinical investigation, Sponsor representatives or designees may visit 
the clinical site where the investigation is to be conducted.  Sponsor representatives or designees 
shall ensure that the Investigator understands the investigational status of the investigational 
product, all requirements of the investigation to be undertaken, and all of his/her responsibilities 
as an Investigator.  Sponsor representatives or designees will also visit the clinical site at 
appropriate intervals as required to ensure compliance with the protocol and to verify the 
accuracy and completeness of data reported on the CRFs.  The Study Director or designees shall 
be available for consultation with the Investigator and serve as liaisons between the clinical site 
and the Sponsor.  
The Sponsor or authorized designees may inspect all documents and records required to be 
maintained by [CONTACT_737], including but not limi ted to medical records (office, clinic, or 
hospi[INVESTIGATOR_307]) and investigational product dispensation logs for the subjects in this clinical 
investigation.  The Investigator must permit access to such records.  The Investigator must 
obtain, as part of informed con sent, permission for an authorized representative of the Sponsor, 
or regulatory authorities, to review, in confidence, any records identifying subjects.  
7.4. Data Quality Assurance  
In order to ensure the collection of accurate, consistent, complete, and reliabl e data during this 
clinical investigation, Sponsor representatives or designees may conduct audits of participating 
sites at appropriate intervals throughout the study.  The results of these periodic site audits may 
be subject to review by [CONTACT_125099].   
All clinical data will undergo a  quality control check prior to clinical database lock. Edit checks 
are performed for appropriate databases as a validation routine using SAS version 9.[ADDRESS_140607], laboratory reports, 
signed informed consent forms, IP disposition records, correspondence with the IRB and Study 
Monitor/Sponsor, AE reports, and information regarding subject discontinuation and completion 
of the clinical investigation.  
All required study data will be recorded on eCRFs .  Any change of data will be recorded on the 
audit trail and a reason for the change will be entered.  
The principal investigator [INVESTIGATOR_78433] a period of at 
least [ADDRESS_140608] article for investigation.  If this requirement differs from any local 
regulations, the local regulations will take precedence unless the local retention policy is less 
than 2 years.   
7.6. Protocol Amendments and Deviations  
No change or amendment to this protocol may be made by [CONTACT_125100](s) or amendment(s) has 
(have) been agreed upon by [CONTACT_125101].  Any change agreed upon  will be 
recorded in writing, and the written amendment will be si gned by [CONTACT_8981] .  
Institutional review board approval is required prior to the implementation of an amendment, 
unless overriding safety reasons warrant immediate action,  in which case the IRB(s) will be 
promptly notified.  
No deviation from the p rotocol will be made except to protect the life or physical well -being of a 
subject in an emergency.  Except in such emer gencies, prior approval of the Sponsor, and the 
IRB, is req uired before deviations from the planned protocol.  All protocol deviations that occur 
during the study will be documented and reported to Sponsor and to the IRB(s) , if applicable, 
according to regulations.  Further details about the documentation, evaluat ion, and follow -up of 
protocol deviations are detailed in this study’s clinical monitoring plan.  
No waivers to inclusion/exclusion criteria will be granted; subjects need to meet all criteria, 
exactly as specified, to be enrolled.  Additionally, prospecti ve deviations from the protocol or 
investigational plan are not permitted except to protect the life or physical well -being of a subject 
in an emergency.  Deviations that occur unintentionally or are the result of action by [CONTACT_125102] d and reported to the IRB(s), if applicable, according to regulations.  Further 
details about the documentation, evaluation, and follow -up of protocol deviations are detailed in 
this study’s  clinical monitoring plan.  
7.7. Confidentiality and Privacy  
The investigat or must assure that subjects’ anonymity will be strictly maintained and that their 
identities are protected from unauthorized parties. Only an identification code and any other 
unique identifier(s) as allowed by [CONTACT_1769] (such as date of birth) will be re corded on any form 
or biological sample submitted to the Sponsor. The investigator agrees that all information 
received from Arcutis  Biotherapeutics , Inc., including but not limited to the investigator 
brochure, this protocol, CRF/eCRF, the IP, and any oth er study information, remain the sole and 
Protocol ARQ -151-[ADDRESS_140609] party (except employees or agents directly 
involved in the co nduct of the study or as required by [CONTACT_2371]) without prior written consent from 
Arcutis  Biotherapeutics , Inc. The investigator further agrees to take all reasonable precautions to 
prevent the disclosure by [CONTACT_69875] . 
7.8. Conflict of Interest  
All study investigators will provide documentation of their financial interest or arrangements 
with Arcutis  Biotherapeutics , Inc., or proprietary interests in the investigational drug under 
study. This documentation must be provided prior to the investigator’s participation in th study. 
All investigators with reported conflict of interst will be required to have such conflicts managed 
in a way that is appropriate to their participation in the design and conduct of this study.  
7.9. Report Format  
According to the ICH Harmonized Tripartite Guideline (Organization of the Common Technical 
Document for  the Registration of Pharmaceuticals f or Human Use M4 and the ICH  M2 Expert 
Working Group), the final report will be written according to the ICH  E3 Guideline 
(Structure  and Content of Clinical Study Reports).  
7.10. Publication Policy  
The Sponsor is supportive of  publishing clinical trial findings.   Any form of publication that is 
derived from this study must be submitted to Arcutis Biotherapeutics Inc. for review and 
approval. The process of coordinating publication efforts is detailed in the Clinical Trial 
Agreement.  
8. REFERENCES  
Baumer W, Hoppmann J, Rundfeldt C, et al. Highly selective phosphodiesterase 4  inhibitors for 
the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets . 2007;6:  
17–26.  
Berger RS, Bowman JP. A reappraisal of the [ADDRESS_140610] in man.  
J. Toxicol Ot & Ocular Toxicol . 1982:1(2);[ADDRESS_140611].  Int. J Clin Pharmacol Ther.   2011;49:51 -57. 
DALIRESP (roflumilast) tablets [package inser t]. [COMPANY_008] Pharmaceuticals LP, Wilmington, 
DE [LOCATION_003]; 2018.  
Dastidar SG, Rajagopal D, Ray A . Therapeutic benefit of PDE4 inhibitors in inflammatory 
diseases. Curr Opin Investig Drugs . 2007;8:364 –372.  
Furue M, Kitahara Y, Akama H, et al . Safety and effic acy of topi[INVESTIGATOR_2855] E6005, a phosphodiesterase 
4 inhibitor, in Japanese adult patients with atopic dermatitis: results of a randomized, 
vehicle -controlled, multicenter clinical trial. J Dermatol . 2014;41:577 -585.  
Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 67 of 95 Grewe SR, Chan SC, Hanifin JM . Elevated leukocy te cyclic AMP -phosphodiesterase in atopic 
disease: a possible mechanism for cy - clic AMP -agonist hyporesponsiveness. J Allergy Clin 
Immunol . 1982;70:452 –457.  
Hanifin JM, Chan SC, Cheng JB, et al. Type [ADDRESS_140612] Dermatol . 1996;107:51 –56. 
Hanifin JM, Thurston M, Omoto M, et al. The eczema area and severity index (EASI): 
assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol.  2001;10:  
11–18.  
Hanifin J.M. and Rajka G.  Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl 
(Stockh ). 1980;92: 44 –47. 
Hatzelmann A, Morcillo EJ, Lungarella G, et al. The preclinica l pharmacology of roflumilast – 
a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary 
disease. Pulm Pharmacol Ther.  2010;23:235 –256. 
Investigator’s Brochure, Edition 1.1, 31 July 2019.  
Murrell DF, Gebauer K, Spelm an L, et al. Crisaborole topi[INVESTIGATOR_125053], 2% in adults with atopic 
dermatitis: a phase 2a, vehicle - controlled, proof -of-concept study. J Drugs Dermatol.  
2015;14:1108 –1112.  
Nazarian R, Weinberg JM . AN-2728, a PDE4 inhibitor for the potential topi[INVESTIGATOR_125054]. Curr Opin Investig Drugs.  2009;10:1236 –1242.  
Newton  et al., Exploring Content and Psychometric Validity of Newly Developed Assessment 
Tools for Itch and Skin Pain in Atopic Dermatitis. Journal of Patient -Reported Outcomes.  2019; 
3:42.  
Nygaard U, Deleuran  M, Vestergaard C.  Emerging treatment options in atopic derma titis: 
topi[INVESTIGATOR_12491]. Dermatology.  2017;233:[ADDRESS_140613]: a review of its use in the treatment of 
COPD.  Int J Chron Obstruct Pulmon Dis.  2016;11:81 -90. 
  
Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 69 of 95 APPENDIX  2. PATIENT HEALTH QUESTIONAIRE -8 (PHQ -8) 
 
 
 

Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 70 of 95 APPENDIX  3. PATIENT HEALTH QUESTIONNAIRE DEPRESSION 
SCALE (MODIFIED PHQ -A) 
 

Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 71 of 95 APPENDIX  4. CHILDREN’S  DEPRESSION INVENTORY 2  (PARENT 
REPORT)  
 

Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 72 of 95 APPENDIX  5. COLUMBIA -SUICIDE SEVERITY RATING SCALE 
(C-SSRS) “BASELINE /SCREENING ” VERSION  
 
 
 
 
 
 
 
 
 
 
COLUMBIA-SUICIDE SEVERITY  
RATING SCALE  
(C-SSRS)   
Baseline/Scr eening Version 
Version 1/14/ 09 
 
  
Posner, K.; Brent, D.; Lucas , C.; Gould , M.; Stanley, B.; Brown, G.; Fi sher, P.; Z elazny, J.; 
Burke, A.; Oquendo , M.; Ma nn, J.  
 
Disclaimer: 
This scale is intended to be used by [CONTACT_24659]. The questions contained in 
the
 Columbia-Suicide Severity Rating Scale are suggested probes. Ultimately, the determination of the presence of suicidal 
ide
ation or behavior depends on the judgment of the individual administering the scale. 
 
 
Definitions of behavioral suicidal events in this scale are based on those used in The Columbia Suicide History Form , 
developed by [CONTACT_24660], MD and Maria Oquendo, MD, Conte Center for the Neuroscience of Mental Disorders 
(CCNMD), [LOCATION_001] State Psychiatric Institute, [ADDRESS_140614], [LOCATION_001], NY, [ZIP_CODE]. (Oquendo M. A., 
Halberstam B. & Mann J. J., Risk factors for suicidal behavior: utility and limitations of research instruments. In M.B. First 
[Ed.] Standardized Evaluation in Clinical Practice , pp. 103 -130, 2003.) 
 
For reprints of the C-SSRS contact [CONTACT_24661], Ph.D., [LOCATION_001] State Psychiatric Institute, [ADDRESS_140615], New 
Yo
rk, [LOCATION_001], [ZIP_CODE]; inquiries and training requirements contact [EMAIL_399]  
© 2008 The Research Foundation for Mental Hygiene, Inc.  
Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 73 of 95  
SUICIDAL IDEATION 
Ask questions 1 and 2.  If both are negative, proceed to “Suicidal Behavior” section. If the answer to 
question 2 is “yes”, ask questions 3, 4 and 5.  If the answer to question 1 and/or 2 is “yes”, complete 
“Intensity of Ideation” section below. Lifetime: Time 
He/She Felt 
Most Suicidal Past  
Months 
1.  Wish to be Dead  
Subject endorses thoughts about a wish to be dead or not alive anymore, or wish to fall asleep and not wake up  
Have you wished you were dead or wished you could go to sleep and not wake up?  
 
If yes, describe:  
Yes       No 
□    □  
Yes     No 
□   □ 
2.  Non-Specif ic Activ e Suicida l Thoughts 
General non-specific thoughts of wanting to end one’s life/commit suicide (eg, “Ive thought about killing myself) without thoughts 
of ways to kill oneself/associated methods, intent, or plan during the assessment period  
Have you actually had any thoughts of killing yourself? 
 
If yes, describe:  
    Yes       No 
    □    □  
Yes     No 
□   □ 
3.  Active Suicida l Ideation with Any Methods (Not Plan) w ithout Intent to Act 
Subject endorses thoughts of suicide and has thought of at least one method during the assessment period This is different than a 
specific plan with time, place or method details worked out (eg  thought of method to kill self but not a specific plan)  Includes person 
who would say, “I thought about taking an overdose but I never made a specific plan as to when, where or how I would actually do 
it…and I would never go through with it.” 
Have you been thinking about how you might do this? 
 
If yes, describe: 
  
    Yes      No 
 □    □  
Yes     No 
□   □ 
4.  Active Suicida l Ideation with Some Intent to Act, without Specif ic Plan 
Active suicidal thoughts of killing oneself and subject reports having some intent to act on such thoughts, as opposed to “I have the 
thoughts but I definitely will not do anything about them.” 
Have you had these thoughts and had some intention of acting on them?  
 
If yes, describe: 
  
   Yes      No 
□    □  
Yes     No 
□   □ 
5.  Active Suicida l Ideation with Specif ic Pla n and Intent 
Thoughts of killing oneself with details of plan fully or partially worked out and subject has some intent to carry it out 
Have you started to work out or worked out the details of how to kill yourself? Do you intend to carry out this plan? 
                                                                        
If yes, describe: 
  
   Yes       No 
 □    □  
Yes     No 
□   □ 
INTENSITY OF IDEATION 
The following features should be rated with respect to the most severe type of ideation (i.e., 1-[ADDRESS_140616] severe).  Ask about time he/she was feeling the most suicidal.  
                                   
Lifetime -           Most Severe Ideation:  _______                  ________________________________________ 
                                                                       Type # (1-5)                                                 Description of  Ideation 
 
Past X Months - Most Severe Ideation:  _______                   ________________________________________ 
                                                                      Type # (1-5)                                                 Description of  Ideation Most  
Severe Most 
Severe 
Frequency  
How many times have yo u had these thoughts?  
(1) Less than once a week    (2) Once a week   (3)  2-5 times in week    (4) Daily or almost daily    (5) Many times each day  
 
____  
 
____ 
Dura tion 
When yo u have the thoughts how long do they l ast? 
(1) Fleeting - few seconds or minutes                                                 (4) 4-8 hours/most of day 
(2) Less than 1 hour/some of the time                                                 (5) More than 8 hours/persistent or continuous 
(3) 1-4 hours/a lot of time ____ ____ 
Controllability  
Could/can you stop think ing about killing yourself or wanting to die if you want to? 
(1) Easily able to control thoughts                                                      (4) Can control thoughts  with a lot of difficulty 
(2) Can control thoughts with little difficulty                                     (5) Unable to control thoughts 
(3) Can control thoughts with some difficulty                                    (0) Does not attempt to control thoughts ____ ____ 
Deterrents 
Are there thing s - anyone or anything  (e.g., family, religion, pain of death) - that stopped you from wanting  to 
die or acting  on thoughts of committing  suicid e? 
(1) Deterrents definitely stopped you from attempting suicide            (4) Deterrents mo st likely did not stop you  
(2) Deterrents probably stopped you                                                    (5) Deterrents definitely did not stop you  
(3) Uncertain that deterrents stopped you                                             (0) Does not apply ____ ____ 
Reasons for Ideation 
Wha t sort of reasons did you have fo r think ing about wanting  to die or killing  yourself?  Was it to end the pain 
or stop the way you were feeling (in other words you couldn’t go on living with this pain or how you were 
feeling ) or was it to get attentio n, reveng e or a reaction from others? Or both? 
(1) Completely to get attention, revenge or a reaction from others       (4) Mostly to end or stop the pain (you couldn’t go on 
(2) Mostly to get attention, revenge or a reaction from others                     living with the pain or how you were feeling) 
(3) Equally to get attention, revenge or a reaction from others               (5) Completely to end or stop the pain (you couldn’t go on  
       and to end/stop the pain                                                                         living with the pain or  how you were feeling) 
                                                                                                                 (0)  Does not apply  
 
____ 
 
  
 
© 2008  Research Founda tion for Mental Hygi ene, Inc          C-SSRS—Baseline/Screening (Version 1/14/09)                                   Page 1 of 2                                     
Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 74 of 95  
SUICIDAL BEHAVIOR 
(Check all that apply, so long as these are separate events; must ask about all typ es)  
Lifetime Past  
Years 
Actual Attempt:  
A potentially self-injurious act committed with at least some wish to die, as a result of act. Behavior was in part thought of as method to kill 
oneself Intent does not have to be 100%  If there is any intent/desire to die associated with the act, then it can be considered an actual suicide 
attempt There does not have to be any injur y or harm, just the potential for injury or harm If person pulls trigger while gun is in 
mouth but gun is broken so no injury results, this is considered an attempt   
Inferring Intent: Even if an individual denies intent/wish to die, it may be inferred clinically from the behavior or circumstances For example, a 
highly lethal act that is clearly not an accident so no other intent but suicide can be inferred (eg, gunshot to head, jumpi[INVESTIGATOR_24608] a 
high floor/story) Also, if someone denies intent to die, but they thought that what they did could be lethal, intent may be inferred  
Have yo u made a suicide attempt? 
Have yo u done anythin g to harm yourself? 
Have yo u done anythin g dangerous where you could have died? 
Wha t did you do? 
Did you______ as a way to end your life?  
Did you want to die (ev en a little) when you_____?  
Were you trying to end your life when you _____? 
Or Did you think  it was possible you could have died from_____? 
Or did you do it purely fo r other reasons / without ANY intentio n of killing yourself (like to relieve s tress, feel b etter,   
get sympathy, or get somethin g else to happen)?  (Self-Injurious Behavior without suicidal intent) 
If yes, describe: 
 
Has subjec t engaged in Non-Suicida l Self-Injurio us Behavior? Yes     No 
□   □ 
 
 
 
 
 
 
 
Total # of 
Attempts 
 
 
 
 
 
 
 
 
 
Yes     No 
□   □ Yes     No 
□   □ 
 
 
 
 
 
 
Total # of 
Attempts 
 
 
 
 
 
 
 
 
 
Yes     No 
□   □ 
Interrupt ed Attempt:   
When the person is interrupted (by [CONTACT_24662]) from starting the potentially self-injurious act (if not for that, actual attempt would 
have occurred). 
Overdose: Person has pi[INVESTIGATOR_125055], this becomes an attempt rather than an interrupted 
attempt Shooting: Person has gun pointed toward self, gun is taken away by [CONTACT_24663], or is somehow prevented from pulling trigger Once 
they pull the trigger, even if the gun fails to fire, it is an attempt Jumpi[INVESTIGATOR_007]: Person is poised to jump, is grabbed and taken down from ledge 
Hanging: Person has noose around neck but has not yet started to hang - is stopped from doing so 
Has there been a  time when you started to do something  to end your life but someone or something  stopped you before 
you actually did anything ? 
If yes, describe: 
 Yes      No 
□   □ 
 
 
 
Total # of 
interrupted 
 
 
 Yes     No 
□   □ 
 
 
Total # of 
interrupted 
 
______ 
 
Aborted Attempt:   
When person begins to take steps toward making a suicide attempt, but stops themselves before they actually have engaged in any self-
destructive behavior Examples are similar to interrupted attempts, except that the individual stops him/herself, instead of being stopped by 
[CONTACT_125103] a  time when you started to do something  to try to end your life but you stopped yourself before you 
actually did anything ? 
If yes, describe: 
 Yes      No 
□   □ 
 
 
Total # of 
aborted 
 
 Yes     No 
□   □ 
 
Total # of 
aborted 
 
 
Prepa ratory Acts or Behavior: 
Acts or preparation towards imminently making a suicide attempt This can include anything beyond a verbalization or thought, such as 
assembling a specific method (eg, buying pi[INVESTIGATOR_3353], purchasing a gun) or preparing for one’s death by [CONTACT_20673] (eg, giving things away, writing a 
suicide note)  
Have yo u taken any steps towards making a suicid e attempt or preparing to kill yourself (such as collectin g pi[INVESTIGATOR_3353], 
getting  a gun, giving  valuables away or writing a suicid e note)? 
If yes, describe: 
  
 
Yes      No 
□   □  
 
Yes     No 
□   □ 
Suicida l Behavior: 
Suicidal behavior was present during the assessment period? Yes      No 
□   □ Yes     No 
□   □ 
Answer for Actu al Attempts Onl y Most Recent 
Attempt 
Date: Most Lethal          
Attempt 
Date: Initial/First 
Attempt 
Date: 
Actual Lethality/Medical Damage:   
0  No physical damage or very minor physical damage (eg, surface scratches) 
1  Minor physical damage (eg, lethargic speech; first-degree burns; mild bleeding; sprains) 
2  Moderate physical damage; medical attention needed (eg, conscious but sleepy, somew hat responsive; second-degree 
burns; bleeding of major vessel) 
3  Moderately severe physical damage; medical hospi[INVESTIGATOR_24610] (eg, comatose with reflexes 
intact; third-degree burns less than 20% of body; extensive blood loss but can recover; major fractures) 
4  Severe physical damage; medical hospi[INVESTIGATOR_24611] (eg, comatose without reflexes; third-degree 
burns over 20% of body; extensive blood loss with unstable vital signs; major damage to a vital area) 
5  Death  
Enter Code 
 
 
 
______ 
 
 
  
Enter Code 
 
 
 
______ 
 
 
  
Enter Code 
 
 
 
______ 
 
 
 
Potential Lethality: Only Answer if Actual Lethality=0 
Likely lethality of actual attempt if no medical damage (the following examples, while having no actual medical damage, had 
potential for very serious lethality: put gun in mouth and pulled the trigger but gun fails to fire so no medical damage; laying 
on train tracks with oncoming train but pulled away before run over) 
 
0 = Behavior not likely to result in injury 
1 = Behavior likely to result in injury but not likely to cause death 
2 = Behavior likely to result in death despi[INVESTIGATOR_125056] 
 
 
 
______ 
  
Enter Code 
 
 
 
______ 
  
Enter Code 
 
 
 
______ 
 © 2008  Research Founda tion for Mental Hygi ene, Inc          C-SSRS—Baseline/Screening (Version 1/14/09)                                   Page 2 of 2                                     
Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 75 of 95 APPENDIX  6. COLUMBIA -SUICIDE SEVERITY RATING SCALE 
(C-SSRS) “SINCE LAST VISIT ” VERSION  
 
 
 
 
 
 
 
 
 
 
COLUMBIA-SUICIDE SEVERITY  
RATING SCALE  
(C-SSRS) 
Since L ast Visit 
Version 1/14/ 09 
 
Posner, K.; Brent, D.; Lucas , C.; Gould , M.; Stanley, B.; Brown, G.; Fisher, P.; Z elazny, J.; 
Burke, A.; Oquendo , M.; Ma nn, J.  
 
 
Disclaimer: 
This scale is intended to be used by [CONTACT_24659]. The questions contained 
in the Columbia-Suicide Severity Rating Scale are suggested probes. Ultimately, the determination of the presence of 
suicidal ideation or behavior depends on the judgment of the individual administering the scale. 
 
 
Definitions of behavioral suicidal events in this scale are based on those used in The Columbia Suicide History 
Form , developed by [CONTACT_24660], MD and Maria Oquendo, MD, Conte Center for the Neuroscience of Mental Disorders 
(CCNMD), [LOCATION_001] State Psychiatric Institute, [ADDRESS_140617], [LOCATION_001], NY, [ZIP_CODE]. (Oquendo M. A., 
Halberstam B. & Mann J. J., Risk factors for suicidal behavior: utility and limitations of research instruments. In M.B. First 
[E
d.] Standardized Evaluation in Clinical Practice , pp. 103 -130, 2003.) 
 
For reprin ts of the C-SSRS contact [CONTACT_24661], Ph.D., [LOCATION_001] State Psychiatric Institute, [ADDRESS_140618], New 
York, [LOCATION_001], [ZIP_CODE]; inquiries and training requirements contact [EMAIL_399] 
 
© 2008 The Research Foundation for Mental Hygiene, Inc.  
Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 76 of 95  
SUICI DAL IDEA TION  
Ask questions 1 and 2.  If both are negative, proceed to “Suicidal Behavior” section. If the answer to question 2 is “yes”, 
ask questions 3, 4 and 5.  If the answer to question 1 and/or 2 is “yes”, complete “Intensity of Ideation” section below. 
 Since Last 
Visit 
1.  Wish to be Dead  
Subject endorses thoughts about a wish to be dead or not alive anymore, or wish to fall asleep and not wake up  
Have you wished you were dead or wished you could go to sleep and not wake up?  
 
If yes, describe: 
  
Yes       No 
 □    □ 
2.  Non-Specif ic Activ e Suicida l Thoughts 
General, non-specific thoughts of wanting to end one’s life/commit suicide (eg, “Ive thought about killing myself) without thoughts of ways to kill 
oneself/associated methods, intent, or plan during the assessment period  
Have you actually had any thoughts of killing yourself? 
 
If yes, describe:  
 Yes      No 
  □    □ 
3.  Active Suicida l Ideation with Any Methods (Not Plan) w ithout Intent to Act 
Subject endorses thoughts of suicide and has thought of at least one method during the assessment period This is different than a specific plan with time, 
place or method details worked out (eg, thought of method to kill self but not a specific plan)  Includes person who would say, “I thought about taking an 
overdose but I never made a specific plan as to when, where or how I would actually do it…and I would never go through with it.” 
Have you been thinking about how you might do this? 
 
If yes, describe:  
 Yes      No 
  □    □ 
4.  Active Suicida l Ideation with Some Intent to Act, without Specif ic Plan 
Active suicidal thoughts of killing oneself and subject reports having some intent to act on such thoughts, as opposed to “I have the thoughts but I 
definitely will not do anything about them.” 
Have you had these thoughts and had some intention of acting on them?  
 
If yes, describe: 
  
Yes       No 
  □    □ 
5.  Active Suicida l Ideation with Specif ic Pla n and Intent 
Thoughts of killing oneself with details of plan fully or partially worked out and subject has some intent to carry it out 
Have you started to work out or worked out the details of how to kill yourself? Do you intend to carry out this plan? 
                                                                        
If yes, describe: 
  
 Yes      No 
  □    □ 
INTENS ITY OF IDE ATION  
The following features should be rated with respect to the most severe type of ideation (i.e., 1-[ADDRESS_140619] severe).  
                                             
Most Severe Ideation:             _____                      _________________________________________________                                                
                                                                                                           Type # (1-5)                                         Descr iption of  Ideation Most 
Severe 
Frequency  
How many times have yo u had these thoughts?  
(1) Less than once a week    (2) Once a week   (3)  2-5 times in week    (4) Daily or almost daily    (5) Many times each day  
____ 
Dura tion 
When yo u have the thoughts, how long do they l ast? 
(1) Fleeting - few seconds or minutes                                                 (4) 4-8 hours/most of day 
(2) Less than 1 hour/some of the time                                                 (5) More than 8 hours/persistent or continuous 
(3) 1-4 hours/a lot of time                                                                    ____ 
Controllability  
Could/can you stop think ing about killing yourself or wanting to die if you want to? 
(1) Easily able to control thoughts                                                      (4) Can control thoughts with a lot of difficulty 
(2) Can control thoughts with little difficulty                                     (5) Unable to control thoughts 
(3) Can control thoughts with some difficulty                                    (0) Does not attempt to control thoughts ____ 
Deterrents 
Are there thing s - anyone or anything  (e.g., family, religion, pain of death) - that stopped you from wanting  to die or acting  on 
thoughts of committing  suicide? 
(1) Deterrents definitely stopped you from attempting suicide            (4) Deterrents mo st likely did not stop you  
(2) Deterrents probably stopped you                                                    (5) Deterrents definitely did not stop you  
(3) Uncertain that deterrents stopped you                                             (0) Does not apply ____ 
Reasons for Ideation 
Wha t sort of reasons did you have fo r think ing about wanting  to die or killing  yourself?  Was it to end the pain or stop the way 
you were feeling (in other words you couldn’t go on living with this pain or how you were feeling) or was it to get attention, 
reveng e or a reaction from others? Or both? 
(1) Completely to get attention, revenge or a reaction from others       (4) Mostly to end or stop the pain (you couldn’t go on 
(2) Mostly to get attention, revenge or a reaction from others                     living with the pain or how you were feeling) 
(3) Equally to get attention, revenge or a reaction from others               (5) Completely to end or stop the pain (you couldn’t go on  
       and to end/stop the pain                                                                         living with the pain or  how you were feeling) 
                                                                                                                 (0)  Does not apply  
 
 
 
____ 
© 2008  Research Founda tion for Mental Hygi ene, Inc          C-SSRS—Since Last Visit (Version 1/14/09)                                 Page 1 of 2                                     
 
Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 77 of 95  
SUICID AL BEHAVIOR 
(Check all that apply, so long as these are separate events; must ask about all types) Since Last 
Visit 
Actual Attempt:  
A potentially self-injurious act committed with at least some wish to die, as a result of act. Behavior was in part thought of as method to kill oneself Intent 
does not have to be 100%  If there is any intent/desire to die associated with the act, then it can be considered an actual suicide attempt There does not 
have to  be any injur y or harm, just the potential for injury or harm  If person pulls trigger while gun is in mouth but gun is broken so no injury results, 
this is considered an attempt   
Inferring Intent: Even if an individual denies intent/wish to die, it may be inferred clinically from the behavior or circumstances For example, a highly 
lethal act that is clearly not an accident so no other intent but suicide can be inferred (eg, gunshot to head, jumpi[INVESTIGATOR_24608] a high floor/story) 
Also, if someone denies intent to die, but they thought that what they did could be lethal, intent may be inferred  
Have yo u made a suicide attempt? 
Have yo u done anything to harm yourself?  
Have yo u done anythin g dangerous where you could have died? 
Wha t did you do? 
Did you______ as a way to end your life?  
Did you want to die (ev en a little) when you_____?  
Were you trying to end your life when you _____? 
Or did you think  it was possible you could have died from_____? 
Or did you do it purely fo r other reasons / without ANY intentio n of killing yourself (like to relieve s tress, feel b etter,  get 
sympathy, or get something  else to happen)?  (Self-Injurious Behavior without suicidal intent) 
If yes, describe: 
 
 
Has subjec t engaged in Non-Suicida l Self-Injurio us Behavior?  
Yes      No 
□   □ 
 
 
 
 
 
 
 
Total # of 
Attempts 
 
 
 
 
 
 
 
 
 
Yes     No 
□   □ 
Interrupt ed Attempt:   
When the person is interrupted (by [CONTACT_24662]) from starting the potentially self-injurious act (if not for that, actual attempt would have 
occurred). 
Overdose: Person has pi[INVESTIGATOR_125055], this becomes an attempt rather than an interrupted attempt 
Shooting: Person has gun pointed toward self, gun is taken away by [CONTACT_24663], or is somehow prevented from pulling trigger Once they pull the trigger, 
even if the gun fails to fire, it is an attempt Jumpi[INVESTIGATOR_007]: Person is poised to jump, is grabbed and taken down from ledge Hanging: Person has noose around 
neck but has not yet started to hang - is stopped from doing so 
Has there been a  time when you started to do something  to end your life but someone or something  stopped you before you 
actually did anything ? 
If yes, describe:  
Yes      No 
□   □ 
 
 
Total # of 
interrupted 
 
 
Aborted Attempt:   
When person begins to take steps toward making a suicide attempt, but stops themselves before they actually have engaged in any self-destructive behavior 
Examples are similar to interrupted attempts, except that the individual stops him/herself, instead of being stopped by [CONTACT_125103] a time when y ou started to do somethin g to try to end your life but yo u stopped yourself before you 
actually did anythi ng? 
If yes, describe: 
  
Yes      No 
□   □ 
 
Total # of 
aborted 
 
 
Prepa ratory Acts or Behavior: 
Acts or preparation towards imminently making a suicide attempt This can include anything beyond a verbalization or thought, such as assembling a 
specific method (eg, buying pi[INVESTIGATOR_3353], purchasing a gun) or preparing for one’s death by [CONTACT_20673] (eg, giving things away, writing a suicide note)  
Have yo u taken any steps towards making a suicid e attempt or preparing to kill yourself (such as collecting  pi[INVESTIGATOR_3353], getting  a gun, 
giving  valuables away or writing a suicide note)? 
If yes, describe: 
  
Yes      No 
□   □ 
Suicida l Behavior: 
Suicidal behavior was present during the assessment period? Yes      No 
□   □ 
Suicide:     Yes    No 
□   □ 
Answer for Actu al Attempts Onl y Most Lethal 
Attempt 
Date: 
Actual Lethality/Medica l Damage:   
0  No physical damage or very minor physical damage (eg, surface scratches) 
1  Minor physical damage (eg, lethargic speech; first-degree burns; mild bleeding; sprains) 
2  Moderate physical damage; medical attention needed (eg, conscious but sleepy, somew hat responsive; second-degree burns; bleeding of major vessel) 
3  Moderately severe physical damage; medical hospi[INVESTIGATOR_24610] (eg, comatose with reflexes intact; third-degree burns 
less than 20% of body; extensive blood loss but can recover; major fractures) 
4  Severe physical damage; medical hospi[INVESTIGATOR_24611] (eg, comatose without reflexes; third-degree burns over 20% of body; 
extensive blood loss with unstable vital signs; major damage to a vital area) 
5  Death  
Enter Code 
 
 
 
______ 
Potential Lethality: Only Answer if Act ual Lethality=0 
Likely lethality of actual attempt if no medical damage (the following examples, while having no actual medical damage, had potential for very serious 
lethality: put gun in mouth and pulled the trigger but gun fails to fire so no medical damage; laying on train tracks with oncoming train but pulled away 
before run over) 
 
0 = Behavior not likely to result in injury 
1 = Behavior likely to result in injury but not likely to cause death 
2 = Behavior likely to result in death despi[INVESTIGATOR_24612] 
 
 
 
______ 
© 2008 Research Foundation for Mental Hygiene, Inc.          C-SSRS—S ince Las t Visit (Version 1/14/09)                                Page 2 of 2                                     
Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 78 of 95 APPENDIX  7. VALIDATED INVESTIGATOR GLOBAL ASSESSMENT 
SCALE FOR ATOPIC DERMATITIS  
 
 
  

Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 79 of 95 APPENDIX  8. DERMATOLOGY LIFE QUALITY INDEX  
 
             DLQI  
Site No:       Date:       Score:  
Name:              
[CONTACT_2761]:      Diagnosis:       
 
The aim of this questionnaire is to measure how much your skin problem has affec ted your life OVER 
THE LAST WEEK.  Please tick  one box for each question.  
 
1. Over the last week, how itchy , sore,     Very much   
 painful  or stinging  has your skin       A lot    
 been?         A little    
         Not at all   
 
2. Over the last week, how embarrassed     Very much   
 or self conscious  have you been because     A lot    
 of your skin?         A little    
         Not at all   
 
3. Over the last week, how much has your     Very much   
 skin interfered with you going       A lot    
 shoppi[INVESTIGATOR_78436]     A little    
 garden ?              Not at all    
Not relevant   
 
4. Over the last week, how much has your     Very much   
 skin influenced the clothes       A lot    
 you wear?        A little    
         Not at all    
Not relevant   
 
5. Over the last week, how much has your     Very much   
 skin affected any social  or      A lot    
 leisure  activities?       A little    
         Not at all    
        Not relevant   
 
6. Over the last week, how much has your     Very much   
 skin made it difficult for       A lot    
 you to do any sport ?      A little    
         Not at all    
        Not relevant   
 
7. Over the last week, has your skin prevented    Yes   
 you from working  or studying ?     No    
        Not relevant   
  
 If "No", over the last week how much has     A lot    
 your skin been a problem at      A little    
 work  or studying ?      Not at all   
 
Protocol ARQ -151-[ADDRESS_140620] week, how much has your     Very much   
 skin created problems with your      A lot    
 partner  or any of your close friends     A little    
 or relatives ?        Not at all    
        Not relevant   
 
9. Over the last week, how much has your     Very much   
 skin caused any sexual        A lot   
 difficulties ?       A little    
         Not at all    
        Not relevant   
 
10. Over the last week, how much of a     Very much   
 problem has the treatment  for your     A lot    
 skin been, for example by [CONTACT_7328]      A little    
 your home messy, or by [CONTACT_78469]?     Not at all    
        Not relevant   
 
 
Please check you have answered EVERY question. Thank you.   
 
 
 
©AY Finlay, GK Khan, April [ADDRESS_140621] not be copi[INVESTIGATOR_78437].  
  
Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 81 of 95 APPENDIX  9. CHILDREN’S DERMATOLOGY LIFE QUALITY INDEX  
 
 
Site No.:  
Name:     [CONTACT_25562]:       CDLQI   
Age:            SCORE:  
Address:     Date:   
 
The aim of this questionnaire is to measure how much your skin problem has  
affected you OV ER THE LA ST WEEK.  Please tick ✓ one box for each question.  
 
1. Over the last week, how itchy , "scratchy" ,    Very much   □ 
 sore or painful  has your skin been?       Quite a lot   □ 
          Only a little   □ 
         Not at all   □ 
 
2. Over the last week, how embarrassed     Very much   □ 
 or self conscious , upset  or sad have you     Quite a lot   □ 
 been because of your skin?       Only a little   □ 
         Not at all   □ 
 
3. Over the last week, how much has your     Very much   □ 
 skin affec ted your friendships ?      Quite a lot   □ 
         Only a little   □ 
         Not at all   □ 
 
4. Over the last week, how much have you changed    Very much   □ 
 or worn different  or special  clothes/shoes     Quite a lot   □ 
 because of your skin?       Only a lit tle  □ 
         Not at all   □ 
 
5. Over the last week, how much has your     Very much   □ 
 skin trouble affected going out , playing ,    Quite a lot   □ 
 or doing hobbies ?      Only a little   □ 
         Not at all   □ 
 
6. Over the last week, how much have you     Very much   □ 
 avoided swimming  or other sports  because                   Quite a lot   □ 
 of your skin trouble?       Only a little   □ 
         Not at all   □ 
 
7. Last week ,    If school time : Over the   Prevented school                □   
          last week, how much did   Very much   □ 
 school time?                   your skin problem affect your  Quite a lot   □ 
     school work ?   Only a little   □ 
    OR        Not at all   □ 
 
 was it       If holiday time : How much  Very much   □ 
 holiday time?                     over the last week, has your  Quite a lot   □ 
     skin problem interfered with  Only a little   □ 
     your enjoyment of the holiday ? Not at all   □ 
 
 was it 
Protocol ARQ -151-[ADDRESS_140622] week, how much trouble     Very much   □ 
 have you had because of your skin with     Quite a lot   □ 
 other people calling you names , teasing ,    Only a little   □ 
 bullying , asking questions  or avoiding you ?   Not at all   □ 
 
9. Over the last week, how much has your sleep     Very much   □ 
 been affected by [CONTACT_117963]?     Quite a lot   □ 
         Only a little   □ 
         Not at all   □ 
 
10. Over the last week, how much of a      Very much   □ 
 problem has the treatment  for your     Quite a lot   □ 
 skin been?        Only a little   □ 
          Not at all   □ 
 
  
Protocol ARQ -151-[ADDRESS_140623] QUESTIONNAIRE  
(DFI ) 
 
Child’s Name:    [CONTACT_125105]/Father/Carer  Date:    Score  
 
The aim of this questionnaire is to measure how much your child’s skin problem has affected you 
and your family OVER THE LAST WEEK.  Please tick  one box for each question.  
 
1. Over the last week , how much effect     Very much    
 has your child having ecz ema had on     A lot     
 housework , e.g. washing, cleaning.     A little     
         Not at all    
 
2. Over the last week , how much effect     Very much    
 has your child having eczema had on     A lot     
 food preparation  and feeding .     A little     
         Not at all    
 
3. Over the last week , how much effect has     Very much    
 your child having eczema had on the sleep    A lot     
 of others in family .      A little     
         Not at all    
 
4. Over the last week , how much effect has     Very much    
 your child having eczema had on     A lot     
 family leisure activities , eg swimming.     A little     
         Not at all    
 
5. Over the last week , how much effect has     Very much    
 your child having eczema had on time spent    A lot     
 on shoppi[INVESTIGATOR_125057].      A little     
         Not at all    
 
6. Over the last week , how much effect has your    Very much    
 child having eczema had on your expenditure ,   A lot     
 eg costs related to treatment, clothes, etc.    A little     
         Not at all    
 
7. Over the last week , how much effect has your    Very much    
 child having eczema had on causing tiredness    A lot     
 or exhaustion  in your child’s parents/carers.    A little     
         Not at all    
 
8. Over the last week , how much effect has your    Very much    
 child having eczema had on causing emotional    A lot     
 distress  such as depression, frustration or    A little     
 guilt in your child’s parents/carers.     Not at all    
 
9. Over the last week , how much effect has yo ur   Very much    
 child having eczema had on relationships    A lot     
 between the main carer and partner  or    A little     
Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 84 of 95  between the main carer and other children    Not at all    
 in the family.  
 
10. Over the last week , how much effect has helpi[INVESTIGATOR_125058]    
 with your child’s treatment  had on the     A lot     
 main carer’s life.       A little     
         Not at all    
 
Please check you have answered EVERY question.  Thank you  
© M.S. Lewis -Jones, A.Y. Finlay 1995  
Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 85 of 95 APPENDIX  11. SCORAD  
 
SCORAD  https://www.ncbi.nlm.nih.gov/pubmed/8435513  
 

Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 86 of 95 APPENDIX  12. PATIENT -ORIENTED ECZEMA MEASURE (POEM)  
 

Protocol ARQ -151-311 Arcutis Biotherapeutics, Inc.  
Original  
19 October 2020  Confidential  Page 87 of 95  
